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1Summary
Human immunodeficiency virus (HIV), the causative agent of Acquired
Immune Deficiency Syndrome (AIDS), is a major infectious disease problem that
affects over 40 million people worldwide, with an estimated 3 million deaths per year.
Although major advances were made in the treatment of HIV-infected individuals, a
protective vaccine or an effective way to eliminate HIV from infected individuals is
still lacking. In this study, I combined cell biology and virology to obtain new insights
into HIV-infection by quantitative electron microscopy. In the first part, I analyzed
the localization of a cellular protein complex, termed ESCRT, recently found to be
essential for HIV release from infected cells. ESCRT was also shown to be involved
in protein sorting into, and formation of, intralumenal vesicles of a specialized
endosomal compartment, the multivesicular body (MVB). ESCRT subunits localized
throughout the endocytic pathway, including the plasma membrane and were found to
be particularly concentrated on tubular-vesicular endosomal membranes but not on
MVBs. Unexpectedly, ESCRT was not redistributed to the presumed site of HIV
budding upon infection, the plasma membrane and endosomes in primary human T
cells and macrophages, respectively. ESCRT localized more to the cell surface in T
cells than in macrophages, collectively suggesting that endogenous ESCRT suffices
for HIV budding. These findings also suggested a previously unknown role for
tubular-vesicular endosomal membranes in the function of ESCRT.
In the second part of this study, the site of HIV budding and release from
infected macrophages was studied in detail by EM. Recent studies suggested that HIV
buds into MVBs of macrophages, thereby accumulating in an intracellular endosomal
storage compartment. Such cellular reservoirs of HIV were proposed to hamper
clearance of HIV from infected individuals. In agreement with previous data, EM
analysis of macrophages showed that virions accumulated in large vacuolar structures.
However, an assay that unequivocally discriminated endosomal membranes from the
plasma membrane revealed a very complex morphology of the plasma membrane,
displaying many protrusions and deep invaginations. HIV budding occurred on such
deep invaginations of the cell surface, leading to the accumulation of virions in
vacuolar structures that were limited by cell surface-derived membranes rather than
endosomal membranes. This finding opens a new perspective on HIV infection of
macrophages, in particular their proposed role in virus persistence. Finally, the
combined studies have important implications for the presumed pivotal role of
MVBs/endosomes in HIV budding as well as the role played by ESCRT in their
biogenesis.
2Zusammenfassung
Das Humane Immundefizienz-Virus (HIV) ist der Auslöser des erworbenen
Immundefizienz-Syndroms (acquired immune deficiency syndrome, AIDS). HIV-
Infektion, weltweit eine der problematischsten Infektionskrankheiten, betrifft etwa 40
Millionen Menschen und tötet schätzungsweise 3 Millionen Menschen jährlich.
Obwohl die Behandlung von HIV-Patienten heute möglich ist, gibt es weiterhin
keinen Impfschutz und keine Heilung. Mit der vorliegenden Arbeit habe ich
Zellbiologie und Virologie vereint, um mittels quantitativer Elektronenmikroskopie
(EM) neue Einblicke in die HIV-Infektion zu gewinnen. Im ersten Teil habe ich die
Verteilung eines zellulären, ESCRT benannten, Proteinkomplexes analysiert. ESCRT
ist essentiell für die Freisetzung von HIV aus infizierten Zellen und spielt sowohl
beim Sortieren von Proteinen in die internen Vesikel eines multivesikulären
endosomalen Kompartiments (multivesicular body, MVB) als auch bei der Bildung
dieser Vesikel eine Rolle. ESCRT fand sich im gesamten endosomalen System
einschliesslich der Plasmamembran, und war besonders an tubulär-vesikulären
endosomalen Membranen, aber nicht an MVBs, angereichert. Entgegen der
Erwartungen führte HIV-Infektion nicht zu einer Umverteilung von ESCRT zu den
Orten der Virusfreisetzung aus Zellen, der Plasmamembran in primären humanen T-
Zellen bzw. Endosomen in Makrophagen. In T-Zellen fand sich mehr ESCRT an der
Plasmamembran als in Makrophagen, was darauf hindeutet, dass endogene ESCRT-
Mengen für die HIV-Freisetzung hinreichend sind. Die Ergebnisse weisen auch auf
eine bisher unbekannte Rolle von tubulär-vesikulären endosomalen Membranen bei
der Funktion von ESCRT hin.
Im zweiten Teil habe ich den Ort der HIV-Freisetzung aus infizierten
Makrophagen mittels EM untersucht. Neuere Studien wiesen darauf hin, dass neu
gebildete HIV-Partikel in die Endosomen infizierter Makrophagen entlassen werden
und somit in intrazellulären Speichern akkumulieren, die die Heilung infizierter
Patienten erschweren könnten. Übereinstimmend mit bekannten Daten zeigte unsere
EM-Analyse von Makrophagen, dass Viren in grossen, intrazellulären Vakuolen
akkumulierten. Eine Methode zur eindeutigen Unterscheidung von endosomalen
Membranen und der Plasmamembran offenbarte aber die komplexe Morphologie der
Plasmamembran mit vielen Aus- und Einstülpungen. In diesen tiefen Einstülpungen,
die nicht von endosomalen Membranen, sondern von der Plasmamembran begrenzt
werden, wurden Viruspartikel freigesetzt und angehäuft. Dieses Ergebnis eröffnet
einen neuen Blickwinkel auf die HIV-Infektion von Makrophagen, besonders deren
mögliche Rolle bei der Persistenz von Viren. Zusammenfassend haben diese Daten
eine wichtige Bedeutung hinsichtlich der scheinbar zentralen Rolle von
MVBs/Endosomen bei der HIV-Freisetzung als auch der Rolle von ESCRT bei deren
Bildung.
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Chapter 1
1. Introduction
1.1 Human Immunodeficiency Virus (HIV)
Since the isolation of Human Immunodeficiency Virus (HIV) in 1983, modern
antiretroviral drug development has transformed HIV infection into a treatable
chronic disease in the developed world. Infection with HIV, the causative agent of
Acquired Immune Deficiency Syndrome (AIDS), nevertheless remains a major
infectious disease problem that affects over 40 million people worldwide, with an
estimated 3 million deaths per year [1]. The course of HIV infection typically starts
with acute viral illness, accompanied by loss of T cells, and is followed by
development of a specific immune response during which T cell numbers are largely
restored. During this second phase, viral load in the blood is controlled by the
immune system and patients are generally asymptomatic, but viral replication is not
eradicated. As viral replication continues, T cells are progressively destroyed, finally
resulting in immune deficiency and the development of AIDS. Introduction of highly
active antiretroviral therapy (HAART) has immensely prolonged the asymptomatic
phase, but a protective vaccine or an effective way to eliminate HIV from infected
individuals is still lacking.
Without doubt future directions of HIV therapy will have to take several
recent findings into account. First, it is now becoming clear that the virus interacts
with its host in a sophisticated way, both by modulating the hosts’ immune response
and by misusing host cell factors to complete the viral life cycle. Targeting of cellular
proteins that play crucial roles in the HIV replication cycle may allow development of
new potent drugs that block HIV replication, but a detailed understanding of the
normal cellular functions of such proteins is essential. Second, cellular reservoirs of
HIV were found to hamper clearance of HIV from infected individuals. Efficient
treatment of HIV infection will depend on detailed knowledge about cellular HIV
reservoirs and the mechanisms of virus storage and release.
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1.1.1 Taxonomy of HIV
Human Immunodeficiency Virus (HIV) is a member of the Lentiviruses, one
of seven genera that belong to the family of Retroviridae [2]. Retrovirus genomes are
of (+)-sense RNA type and are reverse transcribed into double stranded DNA
(dsDNA) by the viral enzyme reverse transcriptase (RT) after virus entry into host
cells. This reverse transcription step is a hallmark of retroviral replication [3].
Lentiviruses are subdivided into five groups, each affecting different species.
The primate lentivirus group is further subdivided into three subgroups of
Immunodeficiency Viruses, HIV-1, HIV-2 and Simian Immunodeficiency Viruses
(SIV). HIV-1 is the most extensively studied immunodeficiency virus as over 90% of
cases of HIV infection in the developed world are due to HIV-1. Three distinct groups
of HIV-1, group M, N and O, which are have emerged from three separate
chimpanzee-to-human transmission events, are known [4]. All three groups display
diversification into subtypes, but HIV-1 group M is believed to be the main group in
the HIV-1 global pandemic. Based on phylogenetic association, it can be subdivided
into multiple groups or subtypes. Furthermore, recombination of various group M
strains constantly gives rise to circulating recombinant forms, with different
geographic distributions. Thus, most HIV-1 laboratory strains are derived from group
M isolates.
1.1.2 HIV structure and genome
Infectious HIV-1 virions are spherically shaped, enveloped particles with a
mean diameter of 125 nm (Figure 1 and [5]). Virus particles are enveloped by a
cellular membrane that is acquired during the process of virus budding from infected
cells and contain a characteristic cone-shaped core that encases the viral RNA
genome and proteins that are required for viral replication. Two copies of the HIV-1
genome are packaged into each infectious viral particle. This RNA genome encodes
for nine proteins: the structural proteins Gag, Gag-Pol and Env, two regulatory
proteins Tat and Rev, and the accessory proteins Vpu, Vpr, Vif and Nef (Figure 2 and
[2]).
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Figure 1: Structure of an HIV-1 particle.
Enveloped mature HIV-1 particles have a mean diameter of 125nm. The viral envelope
consists of a cellular membrane with the incorporated viral Env glycoprotein.  The envelope
encases a conical proteinacious core, which harbors two copies of the viral genome and viral
enzymes. Adapted from Molecular Expressions™ Images from the Microscope, National
High Magnetic Field Laboratory, Florida State University, Tallahassee, Florida, USA.
The 9.3 kilobase (kb) RNA genome of HIV-1 is of (+)-strand polarity and is
flanked by short repeats at both ends (U3 and U5, see Figure 2). Upon infection of a
host cell, the RNA genome is reverse transcribed into dsDNA by the action of the
viral reverse transcriptase (RT) enzyme. During reverse transcription, U3 and U5 are
duplicated, giving rise to the long terminal repeats (LTRs, figure 2). Subsequent
integration of the viral DNA into the host cell genome generates the ‘provirus’, the
integrated form of HIV-1. Transcription of the proviral genome is controlled by a
single promoter in the viral 5’-LTR and generates an approximately 9 kb primary
transcript that has the potential to encode all nine HIV genes.
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Figure 2: Genome organization of HIV-1.
The HIV-1 genomic RNA is reverse transcribed into dsDNA, which is inserted in the
cellular genome, giving rise to the integrated provirus. Transcription from proviral DNA
gives rise to viral transcripts encoding for nine viral proteins (see text for details).
Adapted from web-books.com/MoBio.
The primary HIV-1 transcript is either packaged without further modification
into virus particles, where it serves as the viral RNA genome or serves as an mRNA
template for the synthesis of viral proteins (see section 1.1.4).
1.1.3 HIV proteins and their functions
HIV-1 Gag is the major structural protein of HIV-1 and is thus the
determining factor for virus particle structure and shape. It is expressed as a 55kDa
precursor polyprotein that is cleaved during viral maturation by the viral protease (PR,
see below) into the proteins matrix (MA), capsid (CA), nucleocapsid (NC), p6 and
two spacer peptides, sp1 and sp2 ([6] and figure 3).
Figure 3: Schematic model of the domains in HIV-1 Gag.
HIV-1 Gag is expressed as a polyprotein which is cleaved upon virus release into the Gag
domains MA matrix, CA Capsid, NC Nucleocapsid, and two spacer peptides sp1, sp2.
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HIV-1 Gag assembly at cellular membranes is the driving force for virus
production, and Gag alone is sufficient for the formation of virus-like particles
(VLPs) on cellular membranes [7]. Gag membrane association is mediated by MA,
which is derived from the myristoylated N-terminus of Gag [8]. It binds to
membranes via myristate and a basic cluster motif near its N-terminus. MA is thus
associated with the envelope of budding virus particles, and its insertion into the
virions’ lipid bilayer stabilizes the immature particle [9]. The CA and NC domains
mediate Gag-Gag interactions and oligomerization. Furthermore, NC has nucleic acid
binding properties and is thus responsible for incorporation of the viral genome into
particles [10]. The p6 domain of HIV Gag is crucial for HIV release. It carries two
highly conserved motifs, the so-called late domain (L domain) motifs, which are
required for the final membrane fission event during HIV release.  Deletion of either
of the two L domains in p6 inhibits binding to cellular proteins that are involved in
endosomal protein sorting and recycling (see below) and blocks HIV release [11].
A ribosomal –1 frameshift at the C terminus of the gag reading frame occurs
in about one in twenty of all Gag translation events and leads to the expression of a
Gag-Pol fusion polyprotein. HIV-1 Pol encodes for the viral Protease (PR), reverse
transcriptase (RT), RNAseH and integrase (IN). Dimerization of Gag-Pol molecules
upon viral assembly leads to activation of PR, resulting in autocatalytic PR cleavage
away from Gag-Pol. PR the catalyses cleavage of Gag and Gag-Pol into the above-
mentioned proteins.
The glycoprotein Env is the only viral protein that is stably inserted into the
envelope of mature virus particles. It consists of two glycoprotein (gp) domains, gp41
and gp120, which are generated from a gp160 precursor protein after cleavage by the
cellular furin protease. The gp41 moiety contains the transmembrane domain of Env,
while gp120 is located on the surface of the virion through non-covalent interactions
with gp41; Env mediates CD4 virus receptor binding on the cellular surface and
fusion of the viral membrane with the plasma membrane of the target cell. Thus,
expression of Env on the surface of infected cells can lead to plasma membrane
fusion with an adjacent cell bearing CD4, a process that leads to syncytium formation.
The regulatory proteins Tat and Rev are RNA-binding proteins that bind to
viral transcripts in a sequence-specific manner. Tat is a transcriptional transactivator
that facilitates elongation of viral transcripts by binding to a transactivation response
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element (TAR), whereas Rev facilitates nuclear export of intron-containing viral
DNA by binding to a secondary RNA structure, the Rev response element (RRE).
The accessory proteins of HIV-1, Nef, Vif, Vpr and Vpu are not absolutely
required for HIV-1 replication in most cell types, but they play multiple roles as
virulence factors in the viral life cycle (see table 1).
HIV-1 gene product function(s)
Tat Transcriptional
activator
Binds TAR on viral RNA transcripts, enhances
transcription from viral promoter/ RNA-Polymerase II
elongation
Rev Regulator of
viral gene
expression
Binds RRE on viral RNA, inhibits viral RNA splicing,
promotes nuclear export of incompletely spliced viral
RNA transcripts
Nef ‘Negative
effector’
down-regulates cell surface CD4 and MHC class I
molecules, enhances virion infectivity, alters state of
cellular activation
Vif Viral infectivity
factor
overcomes inhibitory effect of unknown host factor,
stabilizes RT complexes
Vpr Viral protein R promotes cell cycles arrest, facilitates infection of
nondividing cells/ nuclear import of viral genome
Vpu Viral protein U promotes CD4 degradation, influences virion release
Table 1. The functions for HIV-1 regulatory and accessory proteins in the viral
replication cycle.
1.1.4 The HIV-1 replication cycle
HIV infection begins with binding of the gp120 domain of Env to the CD4
receptor on the plasma membrane of a host cell, followed by binding to a chemokine
co-receptor. HIV-1 most commonly uses either of the co-receptors CXCR4 or CCR5,
and thus virus strains are classified as either CXCR4-using (X4), CCR5-using (R5),
or R5X4 strains (which can use both co-receptors), capable of infecting T cells or
macrophages, respectively ([12] and below). Co-receptor binding leads to a
conformational change in the gp41 transmembrane domain of Env, which allows
fusion of the viral envelope with the plasma membrane or endosomal membranes of
the host cell [13]. Consequently, the virus core is released into the cytoplasm, leaving
the viral membrane and envelope proteins behind on the outer surface of the cell.
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Once inside the cell, the core is uncoated in a mechanism that is poorly
understood, and the viral nucleoprotein complex (composed of RNA and the viral
enzymes RT, IN and RNAseH) is released. Catalyzed by RT, the RNA genome is
reverse transcribed into DNA and enters the host cell nucleus as a component of the
pre-integration complex, composed of IN, RT, MA, Vpr and at least one host cell
protein. In contrast to other lentiviruses, HIV-1 is able to translocate its genome
across intact nuclear envelopes (see for instance[14]). By the catalytic action of IN,
the viral DNA is then integrated into the host cell genome; the integrated form of the
HIV genome, the so-called ‘provirus’, can persist latently for long periods in resting
cells. Activation of the host cell results in the transcription of viral DNA into a single
mRNA transcript. In the early stages of gene expression, this transcript is multiply
spliced, giving rise to mRNA templates for the early viral genes tat, rev and nef. The
fully spliced transcripts of the early genes are exported into the cytoplasm, whereas
the incompletely or unspliced viral transcripts of all other viral genes are retained in
the nucleus. Their export depends on expression of the viral protein Rev, which binds
to the Rev-responsive element (RRE) on incompletely spliced RNAs and channels
these into the CRM1-dependent nuclear export pathway [15]. Once the transcripts of
late genes gag, pol, env, vif, vpu and vpr are exported, the proteins are expressed in
the cytoplasm. The Env glycoprotein precursor is synthesized on ER-associated
ribosomes and undergoes modifications such as glycosylation and folding in the
secretory pathway. Gag and Gag-Pol are translated on free ribosomes in the
cytoplasm, from where they are targeted to the virus assembly site.
Gag assembles together with the other viral proteins and two copies of the
RNA genome at a cellular membrane, where the virus then buds away from the
cytoplasm. A final membrane scission event leads to release of immature virus
particles [9]. Immediately after or during release, the viral PR catalyzes self-
proteolysis from the Gag-Pol precursor and cleaves packaged polyproteins, which
leads to major protein rearrangements in the virus and condensation of the conical
core. This process is called maturation and gives rise to fully infectious, mature HIV-
1 particles. A schematic overview of the HIV-1 life cycle is given in Figure 4.
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Figure 4: The HIV-1 replication cycle in T cells.
HIV-1 infection starts with the interaction of virus particles with the CD4 receptor and
chemokine co-receptor (1), followed by fusion of viral and cellular membranes (2) and
release of the viral core into the cytoplasm (3). Reverse transcription of the viral RNA
genome occurs within subviral particles in the cytoplasm (4) and the double stranded
DNA transcript is translocated into the nucleus (5) where it is integrated into the cellular
genome (6). Integrated provirus serves as a template for synthesis of viral RNA
transcripts (7), which are translated into proteins in the cytoplasm (8, 9). The viral Env
protein (8) and Gag/Pol polyproteins (9) are transported via independent pathways to the
plasma membrane. Virus particles assemble and bud from the plasma membrane and are
released as immature particles (10). Subsequent proteolysis of viral proteins generates
mature infectious particles (11). Modified from [16] Chapter 59: HIVs and their
replication.
1.1.5 HIV-1 budding and release
Like most enveloped viruses, HIV-1 is released from infected cells via
budding at a cellular membrane (Figure 4, steps 9-11), which in most cell lines was
shown to be the plasma membrane. The essential steps preceding viral budding are
targeting of Gag to and formation of assembly complexes at the plasma membrane.
How the Gag protein, after its synthesis on free ribosomes in the cytoplasm, is
targeted to the plasma membrane is not entirely clear, but it was recently
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hypothesized that Gag assembles on endosomes and traffics through the endosomal
sorting pathway prior to virus assembly at the cell surface (see for instance [17]).
Cellular proteins that are involved in endosomal protein sorting and recycling were
shown to bind HIV Gag and to be part of viral assembly complexes on the plasma
membrane (see below). Formation of assembly complexes initiates the ‘late’ stages of
HIV release: membrane curvature, formation of viral buds and the final active
membrane fission event that leads to the release of virus particles [11].
The preferred site of HIV release from infected cells is discussed with some
controversy: it is well established that HIV-1 buds from the surface of many cell lines
including monocytic cells [18, 19], and it is generally believed that the virus buds
exclusively from the plasma membrane of primary T lymphocytes. The site of HIV
assembly and release in primary macrophages is, however, less well defined.
Assembly and budding of HIV in monocytes and in vitro differentiated, monocyte-
derived macrophages has been addressed in various electron microscopy (EM) studies
[18, 20-30]. Early ultrastructural studies showed budding from plasma membrane
derived pseudopods [30] or the accumulation in and budding into cytoplasmic
vacuolar structures that seemed to be part of the Golgi complex [20, 24]. Recent data
suggested that these cytoplasmic vacuolar structures are of late endocytic origin [28,
29]. This was based on the observation that viruses collected inside large membrane-
bounded vacuoles and acquired late endosomal proteins such as CD63, lamp-1 as well
as major histocompatibility class II (MHC II) molecules. EM images also suggested
that the virus-filled vacuoles sometimes released their viral content into the
extracellular environment in an exosome-like fashion [28] (for a definition of
‘exosome’, see section 1.4). Based on these observations it therefore seemed
reasonable to propose that in macrophages the virus budded and accumulated in late
endosomes. Upon certain stimuli, for instance contact with T cells, these viruses could
then be released from endosomes into the extracellular environment [31]. This
scenario also fitted the proposal that macrophages may constitute a reservoir of
infectious HIV-1 (see below). However, in vivo this model has not been proven yet.
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1.2 HIV-1 susceptible cells
HIV-1 infects cells of the immune system, namely CD4 positive T
lymphocytes (CD4+ T cells), macrophages and dendritic cells (DCs). Like all cells of
the vertebrate immune system, they originate in the bone marrow, where common
lymphoid and common myeloid progenitor cells are produced upon division of
hematopoietic stem cells [32].
T lymphocytes bear antigen-specific receptors, the so-called T cell receptors
(TCRs) and either of the two co-receptors CD4 or CD8. Naïve T cells travel with the
blood stream to the peripheral lymph nodes, where they recognize and bind antigen
that is presented via MHC II molecules on the surface of DCs. If naïve CD4+ T cells
encounter their specific antigen, they become activated, resulting in proliferation and
differentiation into armed effector T cells, which re-enter the blood stream and
activate macrophages or B lymphocytes displaying specific antigen. Activation of
macrophages and B cells in turn leads to efficient degradation of ingested pathogens
and production of pathogen-specific antibodies, respectively.
Monocytes traveling through the bloodstream either differentiate into
phagocytic macrophages upon entering tissues or develop into precursor DCs.
Precursor DCs differentiate into highly phagocytic immature DCs upon entering
peripheral tissues and efficiently take up pathogens, such as viruses, by
macropinocytosis. This results in activation and maturation of DCs into professional
antigen-presenting cells (APCs), presenting antigen to CD4+ T cells via MHC II
molecules. Thus, DCs are APCs that induce the first line of adaptive immune
response. Phagocytic macrophages bind pathogens via surface receptors, resulting in
macrophage activation, phagocytic uptake of the pathogen and its lysosomal
degradation. Macrophages also act as APCs and present antigen together with co-
stimulatory molecules on their surface, resulting in activation of CD4+ T cells and
induction of an adaptive immune response.
1.2.1 Role of T cells, DCs and macrophages in HIV-1 infection
As CD4 is the primary receptor for HIV binding to the cell surface, CD4+ T
cells are major targets of HIV. Early in the course of infection, most HIV replication
is believed to take place in activated, proliferating CD4+ T cells and thus T cells
account for the major population of newly made virus in infected individuals. Resting
Chapter 1 - Introduction
19
T cells (that do not support HIV replication) may, however, play an important role in
the persistence of the virus [33]. As the average half-life of productively infected T
cells is only about two days, the number of T cells profoundly decreases during the
course of HIV infection, finally leading to a failure of immune response.
The role of DCs in HIV infection is poorly understood. As they express
moderate amounts of CD4 on their surface, HIV can enter DCs, but it is not entirely
clear if DCs can be productively infected with HIV-1. It has been shown that the HIV
glycoprotein can bind to DCs via the cell surface molecule DC-SIGN and that this
interaction leads to viral uptake of virus into a mildly endocytic compartment that
may serve as a viral storage compartment. It was shown that virions are released from
DCs and transmitted to T cells upon contact via ‘virological synapses’ (reviewed in
[34]). This argues for a model in which DCs play a dual role: first, transmission of
endocytosed infectious HIV-1 to T lymphocytes and second, activation of the same T
cells by presenting viral antigen [35, 36].
Macrophages are, besides CD4+ T cells, the major target for HIV-1 infection
[37]. It was shown that HIV is able to replicate in macrophages, although fully
differentiated macrophages do not undergo mitosis. During initial infection,
macrophages are believed to be among the first cells targeted by HIV and they may
contribute to HIV infection in several ways: First, macrophages are less susceptible to
the cytopathic effects of HIV and more resistant to HIV-induced apoptosis compared
to T cells. This allows infected macrophages to survive over long periods of infection
[38, 39] and thus they contribute significantly to persistence of infection. Second,
ultrastructural analysis of HIV-1-infected monocytes and macrophages showed the
presence of virions in intracellular vacuoles [22, 26, 28, 29]. Whether these viruses
accumulate upon de novo replication or, at least partially, represent endocytosed virus
is not entirely clear. In both cases, this intracellular virus-containing compartment
may provide a cellular reservoir of infectious HIV, which is protected from the hosts’
immune system. Third, as HIV-infected macrophages potentially encounter and
activate T lymphocytes in lymphoid tissues, reverse signaling from the T cell to the
infected macrophage may induce directed release of virus particles onto T cells and
thereby support viral spread.
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1.3 The ESCRT protein complex
Endosomal Sorting Complex Required for Transport (ESCRT) is a
multiprotein complex that was originally identified in yeast. Genetic studies in
Saccharomyces cerevisiae identified over 40 vacuolar protein sorting (Vps) factors
[40-43], 18 of which were classified as class E Vps factors. Yeast mutant strains
defective for one of these class E Vps proteins display enlarged, aberrant endosomal
structures, the so-called ‘class E compartment’, and defects in protein sorting to the
vacuole [44]. In yeast, ESCRT functions in the sorting of mono-ubiquitinylated
proteins to the vacuole and is involved in formation of the intra-lumenal vacuolar
vesicles to which ubiquitinylated proteins are targeted for degradation. Some class E
Vps factors, such as Vps27, Vps31 and Vps4 were not found to be part of ESCRT, but
are additionally required for ESCRT function [45-47].
ESCRT is highly conserved from yeast to human, and mammalian homologs
of all known yeast class E Vps proteins have been identified [48-50]. Compared to
yeast, some Vps proteins have up to four isoforms in human cells, and the complex is
therefore composed of at least 19 subunits [50, 51]. The class E Vps factors allocated
to ESCRT were further subdivided into the three subcomplexes ESCRT-I, -II and –III
[52-55]. It is believed that these subcomplexes are recruited to membranes in a
sequential manner.
Many of the initial findings in yeast have recently been confirmed in
mammalian cells. A now well-established function of ESCRT in mammalian cells is
the down-regulation of cell surface receptors. As in yeast, human ESCRT was shown
to mediate targeting of cell surface receptors to the intra-lumenal vesicles of multi-
vesicular endosomes (MVEs) or multivesicular bodies (MVBs), from where the
receptors are transported into lysosomes for degradation. Ubiquitination of cell
surface receptors is an important sorting signal into this pathway, and at least three
ESCRT proteins were shown to have ubiquitin-binding activity (Figure 5 and [56-58],
reviewed in [59]).  Furthermore, ESCRT is believed to be responsible for the
formation of intralumenal MVB vesicles, and mutation of mammalian class E Vps
proteins results in the formation of an aberrant endosomal compartment, similar to the
class E compartment of yeast [60]. Thus, interaction with (endosomal) membranes is
a crucial factor in the well-established functions of mammalian ESCRT. However,
sequence analysis of ESCRT proteins showed that ESCRT subunits have no
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membrane-spanning domains and, with the exception of Hrs, none of the ESCRT
proteins is currently known to be capable of membrane association [61]. Previous
studies suggested that ESCRT proteins were mostly cytosolic, but such localization
studies were mostly based on fluorescence microscopy of overexpressed proteins and
ultrastructural data on ESCRT localization were missing until the onset of this study.
Furthermore, despite extensive data on protein-protein interactions of class E Vps
factors, the function of the entire ESCRT protein network in eukaryotic cells is not
completely understood. It is not clear why human cells have additional Vps protein
isoforms and, because of its higher complexity, it is likely that ESCRT has additional
functions, which may be related to the endocytic pathway, in higher eukaryotes.
Figure 5: The human ESCRT complexes in endosomal sorting.
The Hrs protein is targeted to endosomal membranes via its FYVE domain that binds PI(3)P,
and its UIM domains, which bind ubiquitinated cargo. Hrs subsequently binds and activates
the ESCRT-I complex via the PSAP motif in its C-terminal domain that also interacts with
Tsg101 in ESCRT-I. Ubiquitinated cargo is recognized by ESCRT-I via the UEV domain of
TSG101 and by ESCRT-II (presumably via EAP45). ESCRT-III coordinates the association
of accessory factors such as Aip1/Alix and hypothetical deubiquinating enzymes that remove
ubiquitin from cargo. The AAA-type ATPases Vps4A and Vps4B catalyze the dissociation of
ESCRT complexes. Together, these complexes appear to direct formation of intralumenal
endosomal vesicles and vesicle fission. This speculative model is based on potential
similarities between endosomal vesicle formation in yeast and human. Abbreviations: de-Ub,
deubiquitinating enzyme; Ub, ubiquitin. Adapted from [46].
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1.3.1 The ESCRT proteins Hrs, Tsg101, Aip1/Alix and Vps4
Within this work, four subunits of the ESCRT machinery were studied in
detail. First, hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs, Vps27
in yeast). Second, tumor susceptibility gene 101 protein (Tsg101, Vps23 in yeast).
Third, ALG-2 interacting protein 1/ ALG-2 interacting protein X (Aip1/Alix, Vps31
in yeast) and fourth, the AAA-type ATPase Vps 4B (Vps4 in yeast). Although only
Tsg101 is currently classified as a bona fide ESCRT component, all four proteins
were shown to be required for ESCRT function in mammalian cells.
Hrs binds to membranes via a FYVE domain capable of binding to
phospholipids and two coiled-coil domains that mediate membrane association.
Furthermore, Hrs binds ubiquitinated cargo protein through a ubiquitin-interaction
motif (UIM) and forms a complex with the ubiquitin-binding proteins STAM1,
STAM2 and the endocytic regulator Eps15 [62]. This complex is often referred to as
ESCRT-0. It functions in recruiting mono-ubiquitynated cargo onto (endosomal)
membranes and delivering it to the ESCRT-I component Tsg101. Tsg101 binds
ubiquitinated cargo via its E2 ubiquitin-conjugating domain and recruits other
ESCRT-I components onto endosomal membranes. This is followed by recruitment of
the ESCRT-II and-III complexes and their associated proteins. The ESCRT-
associated class E Vps factor Aip1/Alix was shown to bind both Tsg101 and ESCRT-
III subunits and thus serves as a bridging molecule between ESCRT-I and -III [50].
Finally, the ATPase activities of Vps4A and 4B were shown to be required for
ESCRT function, presumably by disassembling ESCRT complexes and recycling
them for further rounds of protein sorting [60, 63].
1.3.2 ESCRT function in HIV-1 budding and release
Budding of HIV-1 away from the cytoplasm mechanistically resembles the
formation of intra-lumenal endosomal vesicles, consistent with a role for ESCRT in
both processes. Recent literature shows that egress of several enveloped viruses,
including HIV-1, depends on interaction with functional ESCRT complexes [11, 64-
66]. In the case of HIV-1, two highly conserved motifs within the p6 region of Gag
were shown to bind class E Vps proteins [67, 68]. These short amino acid sequences,
a PTAP motif binding to Tsg101 and a LXXLF motif (with X being any amino acid)
binding to Aip1/Alix, are referred to as late domain (L domain) sequences, since
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mutations in these sequences have been shown to play a critical role in the late steps
of the HIV-1 replication cycle [65, 66, 69]. Specifically, binding of L domains to
Tsg101 as well as to the ESCRT-associated protein Aip1/Alix was shown to be
essential for efficient virus release [19, 50, 68, 70], and abrogation of L domain
binding leads to retention of virus buds on the plasma membrane. In analogy with
ESCRT-mediated sorting of ubiquitinated cell surface receptors, ubiquitination was
shown to play a role in the release of HIV-1 and other enveloped viruses that utilize a
PTAP L domain for ESCRT binding. HIV-1 Gag is ubiquitinated at multiple sites and
it was shown that ubiquitin is required for the release of HIV-1 [71, 72]. Recent data
showed that the MA, CA, sp2, NC and p6 domains of HIV-1 Gag are ubiquitinated,
and mutation of multiple ubiquitination sites in these Gag domains dramatically
interfered with HIV-1 release [73], confirming the functional relevance of Gag
ubiquitination.
Since HIV-1 release at the plasma membrane depends on ESCRT, it has been
proposed that HIV-1 Gag actively recruits ESCRT to its site of budding. The latter
idea was supported by immunofluorescence analyses, showing that overexpression of
Gag results in the recruitment of ESCRT to the site of Gag accumulation [69, 74].
However, the latter studies did not analyze the localization of endogenous ESCRT
proteins under HIV-1 infection conditions in detail, and a direct quantitative
comparison of ESCRT localization in HIV-infected and uninfected cells has not been
done before the onset of this work.
1.4 The endocytic pathway
The cellular endocytic pathway functions in uptake of extracellular material
such as proteins and lipids, its intracellular sorting and transport as well as in
recycling and degradation of endocytosed material. This function is carried out by a
morphologically complex network of membrane-bounded endocytic structures,
distributed through the peripheral and perinuclear regions of the cytoplasm [75]. A
simplified classification of endocytic structures found in any vertebrate cell
distinguishes four types of structures: primary endocytic vesicles, early endosomes
(EEs), late endosomes (LEs) and lysosomes (Figure 6). However, the endocytic
pathway comprises a sophisticated network of vacuoles, tubules and vesicles that can
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differ significantly between cell types [76, 77]. The classification of early and late
endocytic structures is generally based on detailed pulse-chase EM analyses with fluid
phase markers (see below) and on immuno-EM labelings with antibodies against
endosomal proteins.
Endocytic uptake of material at the plasma membrane is often initiated by
stimulation of cell surface receptors, followed by receptor-mediated endocytosis. This
process involves invagination of specialized areas of the cell surface and subsequent
formation of small intracellular vesicles carrying internalized transmembrane or
lumenal cargo. Many of these small endocytic vesicles are encased by a proteinacious
coat that assembles from cytosolic proteins that are recruited to the plasma membrane.
A key component of this protein coat is clathrin, which, in association with adaptor
protein 2 (AP2), drives endocytic vesicle formation at the cell surface [78]. Other coat
complexes that mediate clathrin-independent endocytosis have been identified and
their number is still growing [79-81]. One important example of clathrin-independent
uptake is fluid-phase endocytosis, an uptake mechanism that can occur constitutively
without receptor stimulation. Constitutive fluid phase endocytosis and receptor-
mediated endocytosis originate from different plasma membrane regions, and thus
fluid phase uptake gives rise to a different set of (non-coated) early endocytic
vesicles.
It is generally believed that both clathrin-coated and non-clathrin vesicles
enter the same endocytic pathway at the level of EEs, although examples of
convergence of the two systems at later steps of the endocytic pathway have been
reported [82, 83]. Transport of endocytosed material is regulated by a complex
molecular machinery, which delivers endocytic cargo into early endosomes (EEs) and
transports it into a tubulo-vesicular compartment that is defined as the sorting
endosome. From the sorting endosome, cargo is either recycled back to the plasma
membrane (generally referred to as the ‘default pathway’) or transported to late
endosomes (LEs) and then to lysosomes for degradation. Whether transport from EEs
to LEs involves maturation of EEs or occurs via vesicular intermediates (similar to
transport mechanisms within the secretory pathway) is not entirely clear, but
computational three-dimensional analysis of serial cell sections revealed the existence
of discrete endocytic vesicles without membrane continuity to other endocytic
structures [84]. In favor of the latter mechanism is the finding that, upon blocking
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dynein function and therefore directed movement of endocytic vesicles, endocytosed
material accumulates in a distinct spherical endocytic compartment containing
multiple internal vesicles and never reaches LEs [85, 86]. It was therefore postulated
that this compartment, which morphologically resembles MVBs (which they termed
endosomal carrier vesicles or ECVs), was the carrier vesicle mediating transport
along microtubules from peripheral EEs to more perinuclear located LEs (Figure 6).
The idea that ECVs or MVBs are intermediates between EEs and LEs is substantiated
by uptake experiments of fluid phase markers, showing that MVBs are filled with
such markers before LEs (see, for instance, section 3.1.2).
Figure 6: Overview of the endocytic pathway.
For details, see text. Adapted from [87].
With the discovery of ESCRT, the biogenesis of MVBs or multivesicular
endosomes (MVEs) has gained much attention; it is now generally believed that
endosomal cargo destined for degradation first localizes to the limiting membrane of
MVBs/ MVEs, but is then sorted into its internal vesicles. This process seems to be
ESCRT-dependent, and ubiquitination may provide a general sorting signal for cargo
entry into MVBs/ MVEs (see above). ESCRT has furthermore been linked to the
formation of the internal vesicles of MVBs and MVEs [88, 89]. As is clear from the
above, the term ‘MVB’ and ‘MVE’ are generally used indiscriminately in the ESCRT
literature, suggesting that these represent the same structures. However, throughout
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this study we defined MVBs as an intermediate compartment between EEs and LEs
that contains multiple internal vesicles and that has a distinct spherical shape and size.
This is based predominantly on the fact that MVBs take up fluid phase markers before
LEs/MVEs. Furthermore, MVBs generally display low labeling for typical late
endosomal proteins that are abundantly found on MVEs/LEs.
In some cell types such as professional APCs, MVBs can serve as an
intermediate storage compartment, from which intralumenal vesicles can be released
into the extracellular space upon fusion of the limiting MVB membrane with the
plasma membrane. The released vesicles are termed exosomes, and the limiting
membrane of these 40-100nm exosomes was shown to be specifically enriched in
MHC II molecules, which are typical for the late endocytic compartment of APCs
[90].
1.4.1 EM analysis of the endocytic pathway
The endocytic pathways of different cell types vary greatly, both
morphologically and functionally. This reflects the different functions of cells, as
professional APCs, for instance, are specialized in processing and presenting antigen
and are therefore equipped with a complex and extended endocytic system. This cell-
type dependent complexity and diversity of endocytic compartments requires reliable
assays to discriminate, at least roughly, different endocytic compartments. Immuno-
electron microscopy (EM) using antibodies against established endosomal marker
proteins may in some cases not be sufficient since such marker proteins can show cell
type dependent differences in their localization ([91], see also section 3.1.2).
Endocytic uptake of electron dense material into cells prior to their processing for EM
is thus a more reliable method for studying endocytic compartments (see, for instance,
[92, 93]).
To study the endocytic pathway by EM, various endocytic tracer molecules
can be used. Useful molecules have in common that they are electron dense (or
specifically form electron dense reaction products) and are not membrane permeable.
Gold particles are widely used for localizing cell components with a variety of
immunocytochemical techniques, because they can easily be visualized in biological
specimens by various microscopic methods. The particulate nature and electron
density of gold particles allows their simple visualization on thin sections by electron
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microscopy, and gold particles can be prepared with defined diameters and narrow
variation in particle size. Colloidal gold particles associate with a wide range of
organic compounds such as bovine serum albumin (BSA), immunoglobulins (Ig) or
protein A [94]. Conjugates such as BSA coupled to gold particles (BSA gold) are
especially suitable for uptake by fluid phase endocytosis, as BSA gold is readily taken
up into endosomal compartments of endocytically active cells. In ultrathin sections of
such cells, the BSA-gold content of endocytic compartments allows simple and rapid
identification of endosomes without any additional contrasting techniques. The
progression of gold particles through the endocytic pathway can be studied in pulse-
chase experiments and by sequential endocytosis of gold particles with different
diameters. This allows specifying the endocytic pathway by morphology and tracer
uptake kinetics. Combined pulse-chase and immuno-EM experiments with antibodies
to established endosomal markers allow the detailed localization of an antigen
throughout the endocytic pathway.
1.5 Aim of this work
This work aimed at addressing two topics related to HIV-1 budding and
release.
First, we wanted to study the subcellular localization of the ESCRT protein
complex, which was recently found to be essential for HIV release from infected
cells. The aim was to gain insight into the normal localization and function of ESCRT
in HIV-susceptible cells and to test if the ESCRT protein complex was relocalized to
the site of HIV budding upon infection. A direct approach to address these questions
is studying the localization of endogenous ESCRT subunits in HIV-1 susceptible cells
by electron microscopy (EM). Within the first part of this work, subunits the cellular
ESCRT protein complex were localized in great detail by immuno-EM in HIV-
infected and uninfected human T cells and macrophages.
Second, we wanted to determine the site of HIV-1 budding and release in
macrophages. The aim was to examine in detail if HIV-1 particles were released into
an intracellular, endosomal compartment (as recently suggested) or from the cell
surface (as in T cells). The most direct approach to address this question is the
analysis of HIV-infected primary human macrophages by EM. Thus, we used EM to
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study the morphology of primary macrophages and to determine the site of HIV
budding and release in these cells.
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Chapter 2
2. Materials and Methods
2.1 Buffers and solutions
2.1.1 Electron and light microscopy
0.4M PHEM, pH 6.9 240mM PIPES, 100mM HEPES, 8mM
MgCl2, 40mM EGTA; pH 6.9 adjusted
with KOH
0.4M Sodium Cacodylate buffer, pH
7.2
8.56g Sodium Cacodylate ad 100ml; pH
7.2 adjusted with HCl
immuno-EM fixative I 4% PFA, 0.1 GA in 0.1M PHEM (pH 6.9)
immuno-EM fixative II 4% PFA in 0.1M PHEM (pH6.9)
immuno-EM pickup solution 2.3M sucrose, 2% methyl cellulose;
mixed 1+1
grid coating solution 1% Formvar in chloroform
EPON embedding mixture, medium
hardness
10 ml solution A, 10 ml solution B, 300µl
DMP-30
EPON fixative I 2.5% glutaraldehyde (GA) in 0.1M
sodium cacodylate buffer, pH 7.2
EPON fixative II 2% osmium tetroxide in 0.1M sodium
cacodylate buffer, pH 7.2
EPON embedding solution A 50ml DDSA, 31ml glycid ether
EPON embedding solution B 44.5ml MNA, 50ml glycid ether
Fixative for immunofluorescence (IF) 4% PFA in PBS
IF blocking solution 5% FCS, 50mM glycine, in PBS
IF permeabilization solution 0.5% Triton-X100 in PBS
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IF/ EM wash solution 50mM glycine in PBS
immuno-EM blocking solution (PBG) 1% fish skin gelatin, 0.8% BSA, 50mM
glycine in PBS
Reynold’s lead citrate stain 0.44g lead nitrate, 0.55g sodium nitrate in
10 ml freshly boiled double-dH2O, pH12
(adjusted with 1N KOH)
2.1.2 Cell culture and biochemical assays
12x SDS-PAGE stacking gel buffer 1.5M Tris (pH 6.8), 0.4% SDS
3x SDS-PAGE sample buffer 187.5mM Tris (pH 6.8), 6% SDS, 30%
glycerol, 0.003% bromophenol blue, 15%
?-mercaptoethanol
8x SDS-PAGE running gel buffer 3M Tris (pH 8.8), 0.4% SDS
hypotonic buffer 10mM Tris (pH 8.0), 1mM MgCl2
PBMC wash buffer PBS, 2mM EDTA, 0.5% FCS
PBS 140mM NaCl, 5.4mM KCl, 9.7mM
Na2HPO4, 2mM KH2PO4; pH 7.4
PBST 0.1% Tween-20 in PBS
1000x protease inhibitor cocktail aprotinin 1mg/ml H2O, leupeptin1mg/ml
H2O, pepstatin 1mg/ml ethanol
SDS-PAGE running buffer 50mM Tris, 0.38M glycine, 0.1% SDS
TNE buffer 50mM Tris (pH 8.0), 150mM NaCl
Western Blot blocking buffer 5% (w/v) non-fat dry milk in PBST
Western Blot transfer buffer 48mM Tris, 39mM glycine, 0.037% SDS,
20% methanol
2.2 Antibodies
A detailed list of antibodies and working dilutions is provided in appendix II.
Rabbit polyclonal anti-Hrs was a kind gift of Sylvie Urbé (Liverpool University, UK).
Mouse monoclonal anti-Tsg101 was purchased from Biozol (Eching, Germany).
Rabbit polyclonal anti-Aip1/Alix and anti-Vps4B were kind gifts from Wesley
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Sundquist (University of Utah, Salt Lake City, USA), and were affinity purified using
purified antigen as described (von Schwedler 2003). Anti-CD63 was from Sanquin
(Amsterdam, NL), anti-transferrin receptor from Zymed (Berlin, Germany), anti
lamp-1 (H4A3) from DSHB, Iowa, USA and anti-actin (C-11) and anti-14-3-3? and ?
(C-16 and C-17, respectively) from Santa Cruz (Heidelberg, Germany). Culture
supernatant of the monoclonal antibody ‘P5D4’ was a kind gift of Thomas Kreis.
Polyclonal rabbit antiserum against HIV-1 CA was raised against bacterially
expressed and purified protein. Anti-CD63 (1B5, used for immuno EM analyses) was
a kind gift from Mark Marsh (University College London, London, UK), anti-CD63
was from Sanquin (Amsterdam, NL) and anti-CD44 (F10-44-2) from Chemicon
(Hampshire, UK). Rabbit-anti mouse IgG was from ICN biomedicals. Anti-rabbit and
anti-mouse IgG coupled to Cy3 or to horseradish peroxidase (HRP) were from
Dianova, Hamburg, Germany.
2.3 Chemicals and reagents
All chemicals and reagents not listed here were purchased from Sigma,
Heidelberg, Germany or from Merck, Darmstadt, Germany.
2.3.1 Tissue culture reagents
1000x L-glutamine (2M) Gibco BRL, Division of Invitrogen,
Karlsruhe, Germany
1000x penicillin (100.000U/ml), 1000x
streptomycin  (100mg/ml)
Gibco BRL
Dulbecco’s modified Eagle’s Medium
(DMEM, high glucose)
Gibco BRL
EDTA-trypsin Gibco BRL
fetal calf serum (FCS), heat inactivated Gibco BRL
Ficoll Paque™ Plus Amersham Biosciences
human AB serum (HAB), heat inactivated Sigma, Heidelberg, Germany
interleukin-2 (IL-2) Roche Diagnostics, Mannheim,
Germany
phytohemagglutinin (PHA) Sigma, Heidelberg, Germany
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RPMI 1640 Gibco BRL
2.3.2 Chemicals and reagents for biochemistry
acrylamide 30% :bisacrylamide 0.8%
solution
BioRad, Munich, Germany
acrylamide 40% : bisacrylamide 0.2%
solution
annealed siRNAs against Tsg101 and
Aip1/Alix
Ambion, Huntingdon, UK
enhanced chemoluminescence (ECL)
detection system
Amersham Pharmacia, Freiburg,
Germany
Ficoll Paque™ Plus Amersham Pharmacia,
fluorescent mounting medium Dako Cytomation
FuGene6 transfection reagent Roche, Mannheim, Germany
HEPES Biomol, Hamburg, Germany
Hoechst 3342 dye (Hoechst) Sigma, Heidelberg, Germany
Immobilon-P PVDF membrane Millipore, Bedford, MA, USA
Optiprep™ Axis-Shield, Oslo, Norway
Protran® nitrocellulose membrane Schleicher & Schuell, Dassel,
Germany
2.3.3 Electron microscopy chemicals
16% paraformaldehyde (PFA, aqueous
solution)
EMS (Hatfield, USA), Cat. #15710
25% glutaraldehyde (GA, aqueous
solution)
EMS (Hatfield, USA), Cat. #16220
4% osmium tetroxide (OsO4, aqueous
solution)
EMS (Hatfield, USA), Cat. #19150
BSA Fraction V (biomol, Hamburg, Germany), Cat.
#01400
DDSA (EPON hardener) Serva (Heidelberg, Germany), Cat.
#20755
DMP-30 Serva (Heidelberg, Germany), Cat.
#36975
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Formvar Plano, Wetzlar, Germany
gelatin for embedding of immuno-EM
samples
La Bovida, Nanterres, France
glycid ether Serva (Heidelberg, Germany), Cat.
#21045
gold-III chloride Sigma Cat. #G-4022
MNA (EPON hardener) Serva (Heidelberg, Germany), Cat.
#29452
propylene oxide Serva (Heidelberg, Germany), Cat.
#33715
protein A gold (PAG) Utrecht University, Netherlands
Ruthenium Red Serva (Heidelberg, Germany), Cat.
#34580
tannic acid Serva Cat. #35753
uranyl acetate Fluka (Buchs SG, Switzerland)
2.4 Cell biological and virological methods
2.4.1 Cells and cell culture
All cells and cell lines were cultured at 37 ºC and 5% CO2. All cell culture
media were supplemented with 100U/ml penicillin, 100µg/ml streptomycin, 2mM
glutamine and 5 or 10% heat inactivated FCS (referred to as /5% or /10%), unless
otherwise indicated. MT4 cells [95] and primary CD4+ T cells were maintained in
RPMI1640/10%. Primary human macrophages were cultured in DMEM/10% and
10% heat inactivated human AB serum (HAB). 293T cells [96] were maintained in
DMEM/10%. The human 293T cell line is a highly transfectable derivative of the
epithelial 293 cell line into which the Simian Virus 40 (SV40) tumor antigen was
inserted. The human epithelial cell line HeLa (ATCC CCL-2) and its derivatives
HeLaP4 [97] and HeLa SA48 [98] were grown in DMEM/10%. HeLaP4 are stably
transfected with the HIV-1 CD4 receptor and express the CXCR4 and CCR5
coreceptors and are thus infectable with HIV-1. HeLa SA48 stably express sialyl-
transferase (ST) tagged with a vesicular stomatitis virus G protein epitope. Tagged ST
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was shown to localize to the TGN [98] and can readily be detected with the
monoclonal antibody ‘P5D4’.
2.4.2 Isolation of primary cells
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats
of healthy, HIV-1 seronegative blood donors (DRK Blutspendezentrale Mannheim,
Germany) by density gradient centrifugation (Ficoll Paque™ Plus). Buffy coats were
mixed 1:1 with PBS and carefully placed on top of 15 ml Ficoll Paque™Plus in a 50
ml tube. Gradients were centrifuged for 30 min at 2000rpm (Heraeus Megafuge 1.0)
and 4°Cwith slow deceleration. The PBMC layer was harvested, washed twice with
PBS, and red blood cells were lysed by brief suspension (5 seconds) of cells in dH2O.
Lysis was stopped by immediate addition of 45ml of PBS to the cell suspension. This
step was repeated when necessary until no red blood cells were left in the PBMC
pellet.
CD4+ cells were separated from PBMCs by negative magnetic cell sorting
(Miltenyi Biotec CD4+ T Cell Isolation Kit II), as instructed by the manufacturer.
5x106 cells/ml were cultured over night in RPMI/10% with 0.5 µg/ml IL-2 and
medium was replaced on the following day with RPMI/10% + 0.5µg/ml IL-2 and
200U/ml PHA. Every third day one third of medium was replaced with fresh
RPMI/10% with IL-2 and PHA.
To obtain primary macrophages, isolated PBMCs were washed in PBS/2mM
EDTA/0.5% FCS, resuspended in DMEM/5% and 5-7.5 x 107 PBMCs/ml were plated
onto 15cm cell culture dishes in DMEM/5%. Cells were allowed to attach for 2 hours,
after which unattached cells were washed off with PBS. Adherent monocytes were
incubated in DMEM/10% with 10% HAB. After 2 days, cells were washed with PBS,
detached by treatment with PBS/0.005% trypsin and gentle scraping, replated onto 6-
well or 12-well tissue culture plates (2 x 106/ml) and allowed to differentiate into
macrophages for 3-5 days. Medium was replaced with fresh DMEM/10% containing
10% HAB every third day.
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2.4.3 Virus preparation and infections
Infection of MT4 cells and primary T lymphocytes as well as HIV-1 p24
ELISA measurements were done by Baerbel Glass; Infection of primary macrophages
was done By Ina Allespach (both at Virology Department, University of Heidelberg).
MT4 cells were infected with HIV-1 strain NL4-3 [99] by mixing 10% of
previously infected cells with 90% of uninfected cells. Cells were harvested for EM
24 hrs after initiation of co-cultivation. This method routinely leads to productive
infection of >90% of cells, as assessed by immuno-EM of ultrathin sections that were
labeled with an antibody to the viral CA protein (see below).
Virus inoculum for infection of primary CD4+ cells was prepared from MT4
cells infected as above. Virus-containing culture supernatant was cleared by low-
speed centrifugation, filtered through 0.45-µm-pore-size cellulose-acetate filters
(Schleicher & Schuell, Dassel, Germany), and analyzed for antigen content by a CA-
specific enzyme-linked immunosorbent assay (p24 ELISA, [100]). After addition of
Il-2 and PHA, the cell-free supernatant was used directly for infection of
prestimulated CD4+ cells. Three days after infection, the inoculum was replaced with
RPMI/10% + IL-2 and PHA.
Primary human macrophages were infected with HIV-1 strain YU-2 [101] or
Ba-L, a kind gift of Oliver T. Keppler, using 50-75ng CA antigen per 7x105 cells in
DMEM/10% +10% HAB for 2 days. Cells were then washed 3 times with
DMEM/10% containing 10% HAB and maintained as described above. Infection of
primary cells was monitored by p24 ELISA. Cells were fixed when the ELISA signal
reached a plateau (7-10 days for T cells, 12-17 days for macrophages), which
corresponded to infection rates of 40-50% as assessed by anti-CA labeling of
cryosections (see below).
2.5 Biochemical assays
2.5.1 RNA interference (RNAi)
RNAi is an evolutionary conserved process of gene silencing by which
double-stranded short interfering ribonucleic acids (siRNAs) cause sequence-specific
degradation of homologous cellular mRNA. Interaction of siRNAs with the cellular
RNA-inducing silencing complex (RISC) and homologous mRNAs leads to
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endonuceolytic cleavage and degradation of the target mRNA. This results in a
decrease or shutdown of target mRNA translation into protein. Knockdown of target
protein synthesis can be triggered in mammalian cells by transfection of 21-23 bp
siRNA molecules identical with target mRNA sequences.
siRNA transfections of 293T cells were carried out by Stefanie Jaeger,
Virology Department, University of Heidelberg. 293T cells were grown in 6cm dishes
and transfected with siRNAs against Tsg101 or Aip1/Alix applying a standard
calcium phosphate transfection protocol. At 60% confluency, cells were transfected
with 600pmol siRNA, followed by cell splitting after 12 h and a second transfection
with 300 pmol of the same siRNA after another 12 h.  At 48 h after initial
transfection, cells were either lysed in SDS-PAGE sample buffer for Western blot
analysis or fixed for immuno EM as described below.
2.5.2 Transfection of plasmid DNA
For transfection, HeLa or HeLaP4 cells were seeded on glass cover slips in
24-well plates or onto 6 cm dishes in DMEM/10% without antibiotics. After
approximately twelve hours, when cells had reached ~70% confluency, they were
transfected with the expression plasmid for dominant negative Vps4E228Q-EGFP (a
kind gift of W. Sundquist) using FuGene6 transfection reagent as instructed by the
manufacturer. 3.5 µg of DNA were used per 6 cm dish. Medium was replaced with
DMEM/10% + antibiotics after 8 to 12 hours. At 36 hours after transfection, cells
were either fixed with 4% PFA in PBS for IF or as described below for EM.
Alternatively, cells were directly used for membrane flotation experiments (see
below).
2.5.3 Membrane flotation
HeLaP4 or HeLa cells, either transfected with Vps4E228Q-EGFP (see above) or
untransfected were grown until around 90% confluency, washed with ice-cold
hypotonic swelling buffer (10 mM Tris pH 7.4, 1 mM MgCl2 and protease inhibitor
cocktail) and swollen on ice for 15 min in hypotonic buffer. Cells were detached by
gentle scraping in a small volume of hypotonic buffer and lysed on ice by 25 strokes
with a 25-gauge needle. Nuclei were spun down (1.000g, 3min, 4° C) and the
postnuclear supernatant (PNS) was adjusted to 40% Optiprep™. 900µl of PNS were
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placed at the bottom of a SW60 centrifuge tube, successively overlaid with 2.5 ml
28% Optiprep™ in TNE buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA
and protease inhibitor cocktail) and TNE buffer and centrifuged at 165.000g in a
Beckman SW60 rotor for 3h at 4°?C. 500 µl fractions were collected from top to
bottom of the gradient and fractions were either directly mixed with SDS-PAGE
sample buffer or proteins were precipitated from the fractions prior to SDS-PAGE
(blots not shown). For this, 10% trichloroacetic acid (TCA) were added to each
fraction, proteins were precipitated for 20 min on ice, collected by centrifugation (15
min, 13.000 rpm, 4° C), washed once with ice-cold acetone, air-dried and solubilized
over night in SDS sample buffer. Samples were then analyzed by SDS-PAGE and
western blotting.
2.5.4 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blots
SDS-PAGE allows electric-field separation of proteins according to their
mass. The detergent SDS dissociates and unfolds oligomeric proteins. SDS binding to
polypeptides leads to formation of complexes with fairly constant charge to mass
ratios. The electrophoretic migration of such complexes through a gel is therefore
only determined by their mass. Transfer of separated proteins from an SDS-gel onto a
nitrocellulose membrane in an electric field and specific protein detection by
antibodies is referred to as Western Blotting.
SDS-PAGE and Western Blots of HIV-1 infected or uninfected MT4 cell
lysates were done by Dr. Barbara Mueller, Western Blotting of siRNA transfected
293T cell lysates by Stefanie Jaeger (both Department of Virology, University of
Heidelberg). 293T cells were scraped, MT4 and 293T cells were collected by
centrifugation at 1000g for 15 min, washed with PBS and lysed in SDS-PAGE sample
buffer. Cell lysates were separated by SDS-PAGE (15% acrylamide: bisacrylamide,
200 to 1) and analyzed by western blotting as described [50].
For Western Blot analysis of gradient fractions from HeLaP4 or HeLa
membrane flotation experiments, samples were adjusted to 1x SDS-PAGE sample
buffer, boiled for 5 min and proteins were separated on 17.5% low-crosslinking
acrylamide gels (acrylamide: bisacrylamide ratio 200 to 1. Gels were run were run at
100mA (in the stacking gel) -150mA (separating gel) in SDS running buffer. Proteins
were transferred to PVDF or nitrocellulose membranes by semi-dry blotting for 60-
Chapter 2 – Materials and Methods
38
120 min at 1-2.5 mA/cm2 gel, depending on the size of the protein of interest. Stacks
for blotting were assembled as follows: the nitrocellulose membrane and six pieces of
3mm chromatography ‘Whatman paper’ (Schleicher& Schuell), all of the same size as
the gel, were soaked in transfer buffer. Three pieces of paper were placed on the
anode, followed by the membrane, the SDS-gel, another three pieces of paper and the
cathode (bottom to top). After transfer, the membrane was rinsed in deionized water
(dH2O), incubated for 90 min with blocking buffer, rinsed with PBST and incubated
with the primary antibody. Primary antibodies were diluted in PBS/2% BSA and
0.01% sodium azide or in PBS/5% fat-free milk and sodium azide. Dilutions used for
the antibodies are given in appendix II. The membrane was washed three times with
PBST and incubated with the appropriate secondary antibody (diluted in blocking
buffer) coupled to horseradish peroxidase (HRP) for one hour. After washing the
membrane at least three times in PBST, it was developed using enhanced
chemoluminescence (ECL) detection system (Amersham Pharmacia) as instructed by
the manufacturer. Bands were visualized on Fuji SuperRX films.
2.6 Electron and light microscopy
2.6.1 Preparation of gold particles coupled to BSA (BSA gold)
Preparation of colloidal gold solutions and coupling to BSA was done
essentially as described [102]. Homodisperse colloidal gold solutions were prepared
by reduction of gold ions in aqueous solutions by using a mixture of tannic acid and
citrate as reducing agents.
Reduction of gold chloride leads to condensation of metallic gold particles,
with the particle size depending on the amount of reducing agent. Thus, the use of
different concentrations of tannic acid influences the size of the gold particles during
gold sol formation (Table 2) and allows preparation of gold particles in the size range
of 17 to approximately 3 nm [103] with a very narrow variation in particle size.
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Gold particle diameter (nm) 1% Tannic acid for 100ml final solution (ml)
3 5
4 2.5
5 1
6 0.5
7.5 0.25
9.5 0.1
10 0.08
11.5 0.05
14 0.025
Table 2. Influence of the amount of tannic acid on gold particle size during
preparation of colloidal gold solutions.
When 1 ml or more of tannic acid is used, an equal amount of 25 mM potassium carbonate
must be added to neutralize the reducing solution.
Coupling hydrophilic macromolecules such as proteins to gold particles
renders colloidal gold solutions both stable and hydrophilic in aqueous solutions.
Under pH conditions close to the isoelectric point of a protein, incubation of gold
particles with proteins leads to spontaneous and stable coupling at room temperature.
After cooling down the gold solution to room temperature, its pH was adjusted with
pH paper (colloidal gold may block pH electrodes). The isoelectric point of BSA is
around pH 7.0. A final BSA concentration of 0.2% was added and the solution was
incubated for several minutes at room temperature. Depending on particle size, the
absorption peak of BSA gold solutions is between 480 nm and 550 nm, and optical
density (OD) was determined with a spectrophotometer at 520 nm (OD520). BSA-gold
solutions were stored at 4ºC.
A detailed protocol of BSA gold preparation is given in appendix III.
2.6.2 Fluid phase uptake of BSA gold
Primary human macrophages were starved over night in DMEM/5%, followed
by additional 2 hrs of starvation in serum-free DMEM prior to BSA-gold feeding. To
fill endocytic compartments with BSA gold, primary human macrophages were
incubated for the indicated times with BSA coupled to 5nm or 10 nm gold (final
OD520= 10) in DMEM/10% + 10% HAB at 37°C. Excess BSA was washed away on
ice three times with PBS. To fill all endocytic structures including early endocytic
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vesicles and EEs with BSA gold, cells were directly fixed for EM (see below). To
chase the internalized gold to late endocytic structures, cells were incubated for
additional 30 min or 2 hrs at 37 ºC. When indicated, macrophages were fed with BSA
coupled to 16nm gold for 90 min, followed by an overnight chase to label
LEs/lysosomes. In the latter case cells were incubated for 10 min with BSA coupled
to 5nm gold to fill early endocytic structures before fixation.
MT4 cells or primary T cells were fed for 40 min with BSA coupled to 5nm
gold (OD520= 5); The fact that these cells grow in suspension rather than adherent and
their low endocytic activity precluded detailed BSA-gold pulse-chase experiments.
The efficiency of BSA gold was generally lower than in endocytically active
macrophages. Under the given conditions early endosomes and MVBs were labeled
with BSA gold. LEs were generally poorly filled and lysosomes did not contain BSA
gold.
2.6.3 Sample processing for immunoelectron microscopy
Adherent cells were fixed by adding an equal volume of a 2x fixative I
(8%PFA, 0.2%GA in 0.2M PHEM, pH 6.9) to the cell culture medium. After 5-10
min this mixture was removed and replaced with 1x fixative (4% PFA, 0.1% GA in
0.1M PHEM, pH 6.9) for 90-120 min at room temperature. Cells were scraped,
pelleted by centrifugation and either immediately processed (see below) or stored at
4ºC in fixative II containing 4% PFA in 0.1M PHEM, pH 6.9. Suspension cells were
carefully collected by low-speed centrifugation for 10 min, the supernatant was
removed and cells were directly fixed as a pellet with 4% PFA, 0.1% GA in 0.1M
PHEM, pH 6.9 for 90-120 min. If cells were not processed immediately they were
stored as described above.
Fixed cells were processed as detailed in [104]. Cell pellets were washed by
resuspending 4-5 times in PBS-glycine and incubated for 10 min in PBS-glycine at
37ºC to quench aldehyde groups. Cells were then resuspended carefully in 10%
gelatin/PBS, incubated for 5-10 min at 37ºC, pelleted by centrifugation and
immediately placed on ice until the gelatin was hardened. Gelatin-embedded samples
were infiltrated with 2.3M sucrose (as a cryoprotectant) either for 2 hrs at room
temperature or at 4ºC over night on a rotating wheel, mounted onto sample pins and
frozen in liquid nitrogen. 50-70 nm cryosections were obtained with Diatome (DiS-
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Galetzka, Weinheim, Germany) or Drukker (Element Six, Hanau, Germany) diamond
knives in a Leica EM FCS or EM UC6 ultramicrotome (Leica Microsystems,
Wetzlar) at –120ºC. Copper grids were coated with Formvar and a thin carbon layer
for stabilization. Sections were thawed in a drop of pickup solution (2%
methylcellulose: 2.3M sucrose, mixed 1+1) and transferred to coated copper grids.
For immunolabeling, 50-70 nm cryosections were thawed and incubated with primary
antibodies and 5 nm, 10 nm or 15 nm protein A gold (PAG) as described (Griffiths
1993) and contrasted with uranyl acetate, which forms electron dense precipitates by
reacting with phosphate groups of membrane lipids and nucleic acids. Double
labeling was essentially as described by [102]. A detailed immunolabeling protocol is
given in appendix IV.
2.6.4 Sample processing for plastic embedded electron microscopy
Cells were fed with BSA gold as described above. Cell culture dishes were
placed on ice, washed three times with ice-cold 20mM EDTA/PBS to wash off excess
BSA gold and to partially detach cells from the culture dish. After washing, cells were
fixed with 2.5% GA in 0.1M ice-cold Na-Cacodylate buffer, pH 7.2 for 1 hour, during
which cells were allowed to warm up to room temperature. When indicated, the
fixative contained 0.5 mg/ml Ruthenium Red (RR), which was added to stain the cell
surface. RR is a small membrane-impermeable compound that binds to carbohydrate
moieties of the cell surface and can penetrate into very slender invaginations of the
plasma membrane [105]. Cells were washed with 0.1M sodium cacodylate buffer, and
post-fixed for 30-60 min with 2% osmium tetroxide (OsO4) in 0.1M sodium
cacodylate buffer at room temperature. OsO4 is a powerful oxidizing agent and an
outstanding electron dense stain for electron microscopy. Again, the fixative
contained 0.5 mg/ml RR when indicated. Upon post-fixation in the presence of OsO4,
RR forms an electron dense precipitate which stains the cell surface but not
intracellular membranes [106-109]. Cells were washed with 0.1M cacodylate buffer
to remove excess Ruthenium Red, and dehydrated in a graded series of 50, 70, 90 and
100% ethanol at room temperature. During the dehydration step in 70% ethanol, cells
were contrasted with a saturated solution of uranyl acetate in 70% ethanol, either for 2
hours at room temperature or over night at 4ºC. As uranyl acetate is an electron dense
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compound, this step was used for ‘en bloc’ staining of the whole sample. Cells were
then embedded in EPON as described [94].
60-80 nm plastic sections were obtained in a Leica Ultracut UCT microtome
with a diamond knife, washed with dH2O and contrasted for about 2 min with lead
citrate according to [110]. Lead citrate is a widely used stain for cellular components
such as lipids and nucleic acids and presumably reacts with phosphate groups that
have a greater affinity to the lead ion compared to citrate. To avoid reaction of lead
citrate with CO2, which would yield a precipitate of lead carbonate, contrasting was
always done in the presence of potassium hydroxide pellets. All plastic and cryo-
sections were examined with a Zeiss EM10 or a Philips/FEI Morgagni TEM.
2.6.5 EM quantification techniques
Quantification of protein distribution was done essentially as described by
[111, 112]. For quantification of the distribution of ESCRT proteins, samples were
chosen randomly for sectioning and sections were labeled with primary antibodies
and 10 nm PAG. Grids with labeled sections were first examined at low magnification
(100x) in order to find a grid square containing sections, sections were then scanned
systematically in an unbiased fashion at higher magnification (12.500x) and every
gold particle was counted and classified [111, 112]. Per grid a total of 200 gold
particles were counted. Values represent counts from at least two different grids and
three independent labelings. Quantification in primary T cells and macrophages was
done in cells obtained from at least two different donors.
For estimation of labeling densities or reduction of overall labeling upon
siRNA treatment, samples and grids with labeled sections were chosen randomly, and
grid squares containing sections were chosen at low magnification. Pictures were then
taken randomly at 31.500x magnification on at least two different squares per grid
using a Gatan MultiScan™ camera and Digital Micrograph™ software. Labeling
densities were calculated applying standard stereology methods [94]: each picture was
overlaid with a 1cm grid lattice using the open source ImageJ software (available at
http://rsb.info.nih.gov/ij/download.html) with a ‘stereology’ plugin (available at
ftp://rsbweb.nih.gov/pub/nih-image/plug-ins/Ster DropIns.hqx) .  Membrane
intersections of each organelle of interest with the grid were counted and the total
membrane length of each organelle was estimated, taking into account the
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magnification. For calculation of the labeling density per unit of membrane length
(generally 1µm) was calculated by counting gold particles (representing the antigen)
on the same pictures.
2.6.4 Immunofluorescence
Cells were grown on glass cover slips and transfected with Fugene6
transfection reagent as described below. At 36 hrs after transfection, they were
washed with PBS, fixed for 30 min with 4% PFA/PBS at room temperature and
washed three times with 50mM glycine/PBS (PBS-glycine). Cells were permeabilized
for 5 min with 0.5% Triton-X100/PBS, washed 5 times with PBS-glycine, blocked for
10 min with IF blocking solution (5% FCS, 50mM glycine in PBS) and incubated
with the primary antibody (diluted in blocking solution, dilutions are given in
appendix II) for about 30 min at room temperature in a wet chamber. After washing
the cells 5 times with PBS-glycine, they were incubated with the appropriate
secondary antibody coupled to Cy3 (diluted in IF blocking solution) for 30 min as
above. Cells were washed three times with PBS-glycine, three times with dH2O and
mounted onto glass slides with fluorescent embedding medium (Dako Cytomation).
Light microscopy images were taken with a 100x lens on a Zeiss Axiovert 200 light
microscope, using AxioVision program.
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Chapter 3
3. Results
3.1 Localization of ESCRT in T cells and macrophages
In the first part of this study, four selected subunits of the human ESCRT
complex were localized in great detail by immuno-electron microcopy (EM) in both
HIV-1 infected and uninfected T cells and macrophages. The aims of this ultra-
structural localization study were twofold: first, to gain insight into possible unknown
functions of ESCRT, besides protein sorting into and formation of MVBs, in
uninfected mammalian cells. Second, to examine if in HIV-1 infected cells, the
ESCRT protein complex, which was previously shown to be required for HIV-1
release, was actively re-localized to the site of HIV-1 budding and release.
3.1.1 Characterization of antibodies against selected subunits of the ESCRT
machinery
At the onset of this study a panel of previously described antibodies [50, 113]
were tested for immuno-EM. Affinity-purified antibodies against the ESCRT-I
subunit tumor susceptibility gene 101 protein (Tsg101), the ESCRT-associated Vps
factor apoptosis-linked gene 2 (ALG-2)-interacting protein 1/ ALG-2-interacting
protein X (Aip1/Alix) and against the AAA-type ATPase Vps4B, which was
previously shown to be required for ESCRT function, appeared to display specific
labeling on cryo-sections. The antiserum against hepatocyte growth factor-regulated
tyrosine kinase substrate (Hrs) has been described previously [113], and therefore
these four antibodies were used for further study.  Since only Tsg101 is currently
classified as a bona fide ESCRT component, the term ESCRT refers to ESCRT- and
ESCRT-associated proteins throughout the remainder of this study.
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The specificity of the four antibodies was first tested by western blot analysis
of infected and uninfected MT4 cell lysates. The T cell line MT4 was chosen because
it can be readily infected with HIV-1 and expresses high amounts of viral proteins
[95]. Western blots showed bands of the expected molecular weight for all four
antibodies with no obvious difference in expression levels between infected and
uninfected cells (Figure 7 A).
The specificity of two of the antibodies was furthermore demonstrated by
RNA interference (RNAi) experiments in 293T cells. Cells were transfected with
siRNAs specifically interfering with expression of either Tsg101 or Aip1/Alix, lysed
and subjected to SDS-PAGE and western blotting. Western blot analysis showed that
RNAi with Tsg101 or Aip1/Alix expression led to almost undetectable levels of the
respective protein 48 hours after transfection, whereas the expression level of the
other ESCRT protein was not affected. An antibody against the abundant cytoskeletal
protein actin was used to compare the protein amounts loaded onto the gel (Figure 7
B). To confirm the specificity of the antibodies for immuno-EM, cryosections of
293T cells were labeled with anti-Tsg101 or anti-Aip1/Alix after RNAi-mediated
knockdown of either of the two proteins. The labeling density with anti-Tsg101 or
anti-Aip1/Alix antibodies was significantly decreased on labeled cryosections (Figure
7 C), confirming the specificity of the antibodies by EM.
Upon detailed inspection of cryosections, the labeling for both Aip1/Alix and
Tsg101 was found uniformly decreased over all intracellular structures, with the
exception of mitochondria that displayed the same level of (non-specific) labeling
after siRNA treatment. The specificity of the Hrs and Vps4B antibodies was not
further investigated; the antibody to Hrs was previously used for EM [113].
Furthermore, as shown below, all four antibodies displayed a similar labeling pattern,
indirectly confirming their specificity by EM.
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Figure 7: Western blot analysis of Hrs, Tsg101, Aip1/Alix and Vps4B in infected and
uninfected MT4 cells; RNA interference with Tsg101 and Aip1/Alix in 293T cells.
(A) Lysates of HIV-1-infected (+) or uninfected (-) MT4 cells (about 7.5x104 cells per lane)
were analyzed by SDS-PAGE and western blotting with anti-Hrs, anti-Tsg101, anti-
Aip1/Alix, anti-Vps4B and anti-actin antibodies. (B) Lysates of 293T cells, either
untransfected or transfected for 48 h with Tsg101- or Aip1/Alix-siRNA, were analyzed by
SDS-PAGE and Western blotting. Eighty µg of protein were loaded per lane. Controls are
antibodies to the cytosolic 14-3-3? protein, that appears as two bands on SDS-gels (indicated
with arrows), and the membrane-associated transferrin receptor (Tfr). (C) Reduction of the
overall Tsg101- and Aip1/Alix- labeling by EM on cryo-sections of 293T cells transfected
with either Tsg101- or Aip1/Alix-siRNA. Fifty random photographs of labeled cryo-sections
were taken and the average amount of gold particles per µm of membrane length calculated
using standard stereology methods.
3.1.2 Defining endocytic compartments in macrophages and T cells
We next set out to determine the localization of components of the ESCRT
machinery in target cells for HIV-1 infection. Consequently, we focused on primary
human CD4+ T cells, primary human macrophages and the above-mentioned T cell
line MT4. From the proposed role of ESCRT in mammalian cells, protein sorting into
and formation of MVBs, we expected its subunits to localize throughout the endocytic
pathway, perhaps concentrated on MVBs. In contrast to T cells, macrophages have
strong endocytic activity. It seemed thus likely that the endocytic pathways of these
two cell types show some morphologic differences. Therefore, it was necessary to
characterize endocytic organelles in T cells and macrophages prior to localization of
ESCRT components immuno-EM.
To define endocytic compartments, primary macrophages are particularly well
suited since these cells readily take up fluid phase markers such as bovine serum
albumin (BSA) coupled to gold. To identify early and late endocytic compartments,
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BSA coupled to 5nm gold was fed to macrophages for 10 or 30 min, fixed directly, or
after chasing the internalized gold for 30 min or two hours. These gold-feeding
experiments revealed four morphologically distinct endocytic compartments that were
filled with gold sequentially, in a time-dependent manner (Figure 8 A-C and E).
Figure 8. Defining the endocytic compartments in primary human macrophages.
In primary macrophages four different endocytic structures (marked 1 to 4) can readily be
discriminated. In (A) and (B), cryo-sections of macrophages, fed for 10 min with 5 nm
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BSA-gold before fixing, were labeled with anti-Tfr (10nm gold, arrows; arrowheads 5nm
internalized BSA gold). (A) A typical early endosome in a macrophage abundantly filled
with 5nm BSA-gold. (B) Characteristic oval-shaped dense amorphous structure,
abundantly seen in macrophages. (C) Two types of late endosomes/lysosomes in
macrophages; these typically accumulated BSA-gold after an overnight chase period.
Bars-100nm. (D) Schematic summary of the gold uptake experiments and the definition
of early and late endocytic compartments in primary macrophages. For details see text.
(E) Primary macrophages were fed with BSA coupled to 5 nm gold for 10 or 30 min. as
indicated (pulse) and either fixed directly or after the indicated chase times (30 min or 2
hrs). For each gold feeding condition, the four endocytic structures shown in (A) to (C)
were considered and scored as positive if they contained one or more 5nm gold particles.
The numbers represent the percentage of each of the endocytic structures labeled with 5
nm gold. N/a: in the sample generated after a 30 min BSA-gold pulse, no endosomes of
category ‘3’ were found. -75*-: In the sample obtained after 30 min pulse/ 2 hrs chase the
late endocytic structures ‘3’ and ‘4’ were densely packed with gold particles, precluding
visualization of the internal membranes. In this particular sample the type ‘3’ and ’4’
endosomes were therefore counted as one category. Antibody labeling: macrophages
were fed for 90 min with BSA coupled to 16 nm gold and the internalized gold chased
overnight. Before fixing, the cells were fed for 10 min with BSA coupled to 5 nm gold.
Under these conditions, early endosomes (A) accumulate 5nm BSA-gold and the
structures shown in (C) accumulate 16nm BSA-gold, whereas the oval dense structures
(B) are mostly devoid of internalized gold. Cryo-sections of fixed and BSA gold-fed cells
were labeled with anti-lamp-1 or anti-Tfr followed by rabbit anti-mouse and protein A
coupled to 10nm gold. The relative distribution of antibody labeling was then quantified.
The quantification is displayed qualitatively, + representing low labeling, ++ being
abundant labeling while – displays no to very low labeling.
After 10 min of BSA gold internalization, typical early endosomes were
abundantly labeled with 5 nm gold particles (Figure 8 A and E, marked as ‘1’). Upon
increasing chase periods, BSA gold was gradually shifted into endocytic structures
that were defined as late endosomes/lysosomes (Figure 8 C and E, marked ‘3’ and
‘4’). The BSA gold pulse-chase experiments also revealed oval-shaped electron dense
structures that were generally smaller than late endosomes and that appeared to be an
abundant compartment in macrophages (Figure 8 B and E, marked ‘2’). Since these
were filled with gold before late endosomes/lysosomes, they apparently represented
intermediates between early and late endosomes/lysosomes. Finally, MVBs, typical
round membrane structures containing many internal vesicles, were not prominently
seen in macrophages.
We also performed antibody labeling in macrophages using antibodies
directed against transferrin receptor (Tfr) and lysosome-associated membrane
glycoprotein-1 (lamp-1), generally considered to be markers of early/recycling
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endosomes and late endosomes/lysosomes, respectively. For this, we prepared
macrophages in which BSA coupled to 16nm gold was chased overnight followed by
10 min incubation with 5nm BSA gold, to more clearly discriminate between early
and late endosomes. Under these conditions we found that 16nm BSA gold
accumulated in late endosomes/lysosomes (see, for instance, figure 13 F), 5nm gold
was found in early endosomes (Figure 8 A) whereas the oval dense structures (Figure
8 B) were mostly devoid of internalized BSA gold (not shown). The cells with two
sizes of internalized BSA gold were then used to quantify anti-lamp and anti-Tfr
labeling over different endocytic structures (Figure 8 E). Anti-lamp-1 decorated both
the oval dense and the late endocytic structures, whereas early endosomes were
mostly devoid of this marker (Figure 8 E). We unexpectedly found that anti-Tfr also
decorated mainly late endosomal structures (including the oval dense compartments;
Figure 8 E) and only about 30% of this marker was found on typical early endosomes.
The BSA-gold feeding and antibody labeling experiments also revealed two
types of tubular-vesicular membranes that were part of the endocytic pathway. First,
tubular-vesicular membranes that were apparently part of the early endocytic pathway
since they readily filled with BSA-gold during a 10 to 30 min pulse and were found
close or connected to early endosomes (for an example see figure 13 A). Second,
tubular-vesicular membranes that were, albeit inefficiently, filled with BSA-gold after
a 30 min chase period. This second type of tubular-vesicular membranes was
furthermore found close to late endosomes and often located between late endosomes
and the Golgi complex. Since these membranes (for examples see figures 13 F, 14 A
and B, 15 A and B) labeled significantly with anti-Tfr, they might be (part of)
recycling endosomes.
Throughout this study we defined early endocytic compartments as structures
that were readily filled after 10 min BSA gold uptake and that were anti-Tfr positive,
but mostly devoid of anti-lamp-1 labeling. Late compartments were those gradually
filled with BSA gold after a chase period and that were lamp-1 positive, thus
including the oval dense structures, prominently seen in macrophages (see figure 8 D
for a model).
Compared to macrophages, fluid phase uptake was poor in primary T cells and
MT4, precluding detailed BSA gold pulse-chase experiments. In MT4 cells we
nevertheless found that after a 40 min pulse, early endosomes were readily filled with
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BSA gold, whereas late endocytic compartments were mostly devoid of BSA gold. In
contrast to macrophages, MVBs were readily seen in MT4 cells and could be
discriminated from late endosomes because they were significantly filled with BSA
gold after a 40 min pulse (see figure 14 D and E). Finally, similar to macrophages,
anti-lamp-1 and anti-Tfr labeled mostly late endocytic structures in both MT4 and
primary CD4+ T cells. Having operationally defined the different endocytic
structures, we next quantified the distribution of ESCRT proteins in uninfected cells.
3.1.3 ESCRT- and ESCRT-associated proteins are differentially distributed in
different cell types
Cryosections of MT4 cells, primary human T cells and macrophages were
labeled with antibodies directed against ESCRT proteins Hrs, Tsg101, Aip1/Alix and
Vps4B and the labeling was quantified as described [111, 112]. Endocytic
compartments were defined as described above for macrophages and MT4 cells
(using internalized BSA gold as marker) or based on morphological similarity for
CD4+ T cells. We found that the relative intracellular distribution of the labeling was
similar for each of the four antibodies (Figure 9 A-C), indicating that ESCRT proteins
largely co-localize. Unexpectedly, 80% of the signal was associated with membrane
structures in each cell type, with only around 10-15% in the cytoplasm (Figure 9 A-
C). In T cells (both MT4 and CD4+ T cells) about 15% of the labeling was detected at
the plasma membrane with less than 8% on endosomes (Figure 9 A and B), whereas
this distribution pattern was essentially reversed in primary macrophages (Figure 9
C). Importantly, in all three cell types the majority of labeling (around 45%) was
found associated with a specific set of endosomal membranes (Figure 9 A-C). More
specifically, we found that ESCRT was predominantly located on the two types of
tubular-vesicular membranes described above that were in close proximity or
connected to either early or late endosomes and thus these membranes were
denominated ‘endosome-associated’.
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Figure 9: Quantification of the localization of ESCRT subunits in uninfected cells by
EM.
Thawed cryosections of (A) MT4 cells (B) Primary human CD4+ lymphocytes and (C)
Primary human macrophages were labeled with anti-Hrs, anti-Tsg101, anti-Aip1/Alix or
anti-Vps4B followed by protein A gold. Quantification was done on MT4 cells with 5nm
BSA-gold internalized for 40 min prior to fixing. In the case of macrophages
quantification was on cells prepared with two size of internalized BSA-gold as described
for figure 8 E. ER endoplasmic reticulum, NE nuclear envelope. A total of 200 gold
particles were counted per grid in random sections and attributed to the different
categories indicated. Each experiment was repeated at least twice and two grids were
counted per experiment. The data represent the relative distribution of gold labeling over
different cellular structures, calculated as an average of all experiments and grids. For
primary T cells and macrophages the gold counting was performed on sections of cells
obtained from at least three different donors. Error bars denote standard deviation.
This quantitative method attributed percentages of labeling to specific
organelles irrespective of the size of these membrane structures, which may differ
considerably between cell types. To address this, we quantified the relative membrane
length of plasma membrane and endosomes (excluding the tubular vesicular
membranes) in T cells and macrophages (Figure 10 A). Random pictures of primary T
cells and macrophages were overlaid with a grid lattice and intersections of the
plasma membrane and of endosomes with the grid were counted on each frame to
determine the total membrane length of these two compartments. This quantification
revealed a ratio of total plasma membrane- to endosomal membrane length of 2.2 to 1
in T cells and of 1.7 to 1 in macrophages (Figure 10 A). Next, the anti-Hrs and anti-
Aip1/Alix labeling densities per unit length of membrane were determined on these
two compartments for both cell types (Figure 10 B). For this, gold particles per µm
membrane length on the plasma membrane and on endosomes were counted on the
same randomly taken frames.
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Figure 10: Plasma membrane to endosomal membrane length ratio and labeling
densities of Hrs and Aip1/Alix in T cells and macrophages.
(A) 50 random pictures per cell type were taken at 31.500x magnification, overlaid with a 1
cm grid lattice and intersections of the respective membrane type, plasma membrane and
endosomal membrane, with the grid were counted. Average membrane length of plasma
membrane and endosomal membranes per picture (frame) was calculated from total numbers
of intersections with each membrane and ratio of plasma membrane to endosomal membrane
length was calculated for both cell types. pm plasma membrane; endo endosomal membrane.
(B) Quantification of Hrs- and Aip1/Alix labeling densities on the same random pictures as in
(A). 1 Random pictures were taken from two different labeling experiments for each antibody.
Labeling density was determined on the plasma membrane and on endosomes, taking only
clearly identifiable endosomes into account and not the tubular-vesicular endosomal
membranes. Numbers were determined by applying standard stereology methods. 2 Errors
denote standard error of the mean.
In primary CD4+ T cells, the labeling densities of Hrs and Aip1/Alix were
approximately the same on the plasma membrane and on endosomes (Figure 10 B).
Given a ratio of plasma membrane to endosomal membrane of 2.2 to 1 in these cells
(see figure 10 A), 2.1- and 2.5-fold more labeling for Hrs and Aip1/Alix, respectively,
was therefore found at the cell surface compared to endosomes. This number
corresponds well to the two-fold (Hrs and Aip1/Alix) higher labeling at the cell
surface measured by quantifying their relative intracellular distribution (Figure 9 B)
and confirms that in T cells ESCRT was more abundant at the plasma membrane than
on endosomes. Similar quantification in macrophages, with a plasma membrane to
endosome ratio of 1.7 to 1, showed that the labeling density for both antigens was
about two-fold higher on endosomes compared to the plasma membrane (Hrs: 2.0-
fold, Aip1/Alix: 2.7-fold; figure 10 B), confirming the data shown in figure 9 C. This
quantification also confirmed that the labeling density for both Aip1/Alix and Hrs on
endosomes was more than twice as high in macrophages compared to T cells.
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Thus, the relative ESCRT distribution may vary between cell types. The
quantitative EM data furthermore unexpectedly revealed that most of the labeling was
associated with membranes, with the majority being associated with tubular-vesicular
membranes in the vicinity of, or continuous with, endosomes.
3.1.4 ESCRT antibodies detect both cytosolic and membrane-bound antigen
Our EM observations clearly showed that 80 to 90% of each of the four
ESCRT subunits tested were associated with membranes (Figure 9). This finding was
unexpected since sequence analysis of the four proteins showed that none of them had
a membrane-spanning domain and, with the exception of Hrs, which has a FYVE
domain that targets Hrs to membrane lipids, none of the proteins tested had a
membrane-targeting domain. Furthermore, it was previously shown that that the bulk
of ESCRT proteins comprised a cytosolic pool that was ‘recruited’ to membranes
upon overexpression of a ATPase deficient variant of Vps4 that functions as a
dominant negative (dn) protein [63, 114]. These data were largely based on
immunofluorescence studies and suggested that overexpression of dnVps4 tagged
with green fluorescent protein (dnVps4E228Q-EGFP) leads to the formation of aberrant
enlarged endosomal structures onto which ESCRT complexes are recruited and
trapped [63, 114]. Consistent with the latter studies, the four antibodies displayed a
diffuse pattern by fluorescence microscopy in HeLa cells (Figure 11 A, E), interpreted
previously as ‘cytoplasmic’ labeling [62, 114-116]. Furthermore, over-expression of
Vps4E228Q-EGFP led to the formation of large GFP-positive structures (Figure 11 C,
G) that were labeled with antibodies to Hrs (Figure 11 B, D), Aip1/Alix (Figure 11 F,
H), Tsg101 and Vps4B (not shown), confirming the above mentioned light
microscopy studies. By EM, the Vps4 E228Q-induced structures appeared as enlarged,
GFP-positive, multi-vesicular membrane structures (Figure 11 I, J). The latter were
also decorated with antibodies to Hrs (Figure 11 I), Tsg101 (Figure 11 J) as well as
Aip1/Alix and Vps4B (not shown).
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Figure 11: ESCRT-proteins localize to aberrant, dnVps4E228Q-induced membrane
structures.
HeLaP4 cells were either mock-transfected (A, E) or transfected with dnVps4-EGFP
(Vps4E228Q-EGFP; B-D, F-H) for 36 hours. (A) to (H) Cells were fixed with PFA,
permeabilized and labeled with anti-Hrs (A, B) or anti-Aip1/Alix (E, F). GFP fluorescence is
depicted in (C) and (G) with panels (D) and (H) showing the merge of the two signals. In
untransfected cells (A) and (E), the proteins display a diffuse localization by light
microscopy. Partial redistribution of Hrs and Aip1/Alix to the GFP-positive class E
compartment (C and G) is observed upon Vps4E228Q-EGFP expression. Bars-10µm. (I, J)
Cryosections of Vps4E228Q-EGFP-transfected HeLa cells were double-labeled with anti-GFP
(10nm) and anti Hrs (15nm) (I, arrowheads) or anti-Tsg101 (15nm, J, arrowheads). Enlarged,
GFP-positive aberrant endosomal structures display anti-Hrs- or Tsg101 labeling. Bars-
500nm.
To test if the antibodies used detected their antigen preferably in the soluble
state or in fully assembled ESCRT complexes, we next quantified the overall labeling
density of ESCRT antibodies in HeLa cells overexpressing dnVps4E228Q-EGFP
compared to untransfected cells. It was shown previously, that in dnVps4E228Q-EGFP
expressing cells the bulk of ESCRT proteins is present in fully assembled ESCRT
complexes, whereas in untreated cells the majority of ESCRT is believed to be
disassembled [62, 114-116]. Thus, thawed cryosections of HeLa cells, either
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untransfected or dnVps4E228Q-EGFP transfected, were double labeled with antibodies
directed against GFP and against ESCRT proteins. dnVps4-EGFP expressing cells
were identified by anti-GFP labeling and the average amount of gold particles per cell
profile was estimated in untransfected and transfected cells. This quantification
revealed that the labeling density for Tsg101 and Hrs was similar in both transfected
and untransfected cells (Figure 12 A), indirectly showing that disassembled and
assembled forms of ESCRT complexes are detected equally well by the antibodies.
This excluded the possibility that the unexpected high degree of membrane
association of ESCRT proteins seen by EM was due to the inability of antibodies to
detect the cytosolic pool of antigen.
The same labeled cryosections were then used to determine if ESCRT proteins
were quantitatively recruited to Vps4E228QEGFP-expressing endosomal structures. To
this end, we quantified the distributions of Hrs and Tsg101 over the plasma
membrane, endosomes and tubular-vesicular membranes by EM (Figure 12 B). Anti-
Hrs and anti-Tsg101 labeling on endosomes, including anti-GFP-positive endosomal
structures in transfected cells, was increased about 2-fold compared to untransfected
control cells (25% versus 12% of total labeling), while the plasma membrane labeling
for both antigens was decreased by a factor of 3 (15 versus 5%, figure 12 B). In
contrast, the amount of labeling on the tubular-vesicular endosomal membranes or in
the cytoplasm was mostly unaffected (approximately 25% and 10%, respectively, see
figure 12 B and not shown). This quantitative relocation of ESCRT to enlarged
endosomal structures confirmed our light microscopy data and previously published
observations, showing a clear re-localization of ESCRT to distinct (membrane)
structures upon over-expression of dnVps4-EGFP. Furthermore, this demonstrated
that the antibodies used were able to detect the complete pool of antigen, including
fully assembled ESCRT complexes and soluble proteins. However, whereas in
untransfected cells ESCRT proteins displayed a diffuse pattern by light microscopy,
quantitative EM showed that the majority of these proteins were associated with
membranes.
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Figure 12:  Overexpression of Vps4E228Q–EGFP leads to a redistribution of ESCRT but
does not change overall labeling density or membrane association of ESCRT proteins.
HeLa cells were either transfected with a dominant-negative Vps4-EGFP construct
(dnVps4–EGFP) or left untransfected (control). (A) Quantification of the absolute numbers of
gold particles (representing anti-Hrs or anti-Tsg101 labeling) on thawed cryosections of HeLa
cells. Values represent counts on at least 10 transfected and 10 control profiles per antibody.
Error bars denote standard deviation. (B) Quantification of ESCRT redistribution upon
Vps4E228Q–EGFP overexpression. Cells were treated as in (A) and gold particles were counted
on the plasma membrane, endosomes and tubular-vesicular membranes of transfected and
control cells. At least 200 gold particles were counted per antibody. Values were collected in
two different labeling experiments and two different grids per experiment. (C) Western blot
analysis of gradient fractions from membrane flotation experiments. HeLa cell lysates, either
Vps4E228Q–EGFP transfected or untransfected, were separated on Optiprep gradients, eight
fractions were taken from top to bottom of the gradient and analyzed by western blotting,
using antibodies directed against Hrs, Tsg101, Aip1/Alix, the cytosolic protein 14-3-3? that
appears as three bands on SDS gels (arrows) and the membrane protein transferrin receptor
(Tfr).
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3.1.5 ESCRT proteins are loosely associated with membranes
We next sought to study the membrane association of ESCRT proteins
biochemically. As the four ESCRT subunits tested were found mostly on membranes
by EM but had no membrane-spanning domains, we expected them to be only loosely
associated with membranes. The extent of membrane binding was therefore tested
using membrane flotation of non-detergent HeLa lysates. HeLa cells were
mechanically homogenized, nuclei were gently spun down and post-nuclear
supernatants were subjected to membrane flotation. Gradient fractions were then
collected from top to bottom and analyzed by western blotting using three of the four
selected antibodies (Figure 12 C). As expected, the majority of ESCRT proteins was
detected in the bottom (cytosolic) fractions of the gradient, together with the cytosolic
14-3-3 protein, (Figure 12 C, left panel). Only a minor fraction was found in the top
(membrane) fraction, together with the transmembrane protein transferrin receptor
(Tfr).  Importantly, transfection of HeLa cells with Vps4E228Q-EGFP, which is
believed to lock ESCRT complexes onto membranes, did not significantly increase
the membrane-bound fraction of ESCRT proteins, although transfection efficiency
was above 50%, as determined by direct fluorescence microscopy (data not shown).
We concluded that ESCRT proteins were lost from membranes during mechanical
lysis, indicating that they were only loosely associated with membranes.
3.1.6 Proteins of the ESCRT machinery localize predominantly to tubular-
vesicular endosomal membranes
The four ESCRT proteins were next localized in detail by immuno-EM.
Primary macrophages were used predominantly, because the endosomal compartment
of these cells could readily be filled with BSA gold. However, since typical MVBs
were sparse in macrophages, we also localized ESCRT in MT4 cells, in which this
endosomal structure is more prominently seen.
Consistent with the observations by Sachse et al. [113], anti-Hrs readily
labeled early endocytic structures that were filled with 5nm BSA gold fed to cells 10
min before fixing (Figure 13 A-D). Furthermore, in agreement with their
observations, we also found Hrs associated with a conspicuous membrane coat, which
has previously been implicated in the recruitment of ubiquitinylated proteins (Figure
13 A, B). Hrs was, however, predominantly found on membranes continuous, or close
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to early endosomes (Figure 13 C, D). Although mostly associated with early
endosomal membranes, significant labeling for Hrs was also found on late endosomes
(Figure 13 G) in particular on the tubular-vesicular membranes continuous with or
closely apposed to late endosomes (Figure 13 E-G).
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Figure 13. Ultra-structural localization of Hrs in primary human macrophages.
Primary macrophages were fed for 90 min with BSA coupled to 16nm gold particles followed
by a chase overnight. Before fixing, macrophages were fed for 10 min with 5nm BSA gold to
fill early endosomes (EE). As mentioned in figure 8 E, under these conditions 16nm BSA
gold accumulates in late endosomes/lysosomes (LE) but not in the oval-shaped dense
amorphous structures (OD) of late endocytic origin. (A)-(D): Hrs (arrows) localizes to early
endosomes (EE) abundantly filled with 5 nm BSA gold. In (A) and (B), anti-Hrs labeled an
electron-dense coat on early endosomes. In (C) and (D), Hrs was found on the gold-filled
early endosomes as well as on tubular-vesicular membranes close by (arrows). (E) to (G)
show several oval-shaped dense structures (OD) and (F) one late endosome/lysosome (LE)
that is filled with 16nm BSA gold. Low labeling for Hrs (arrows) was found on the oval-
shaped dense structures as shown in (G), but more abundant labeling was found on tubular
vesicular membranes next to these structures and next to late endosomes. Bars-100nm.
We next performed double-labeling experiments to confirm that the tubular
vesicular membranes were of endocytic origin. Both on the ‘early’ (not shown) and
‘late’ tubular-vesicular membranes Hrs was found to co-localize with Tfr (Figure 14
A and B), indicating that these membranes might be part of recycling endosomes.
Because the ‘late’ tubular-vesicular membranes were generally inefficiently filled
with BSA gold and often closely apposed to the Golgi complex, we suspected that
some of these membranes belonged to the trans-Golgi network (TGN) rather than late
endosomes. By EM, TGN markers (TGN46, GRP94) invariably labeled the TGN as
well as endocytic organelles and were therefore not suitable to unequivocally solve
this question (data not shown). We therefore chose to use SA48 HeLa cells, which
stably express sialyl-transferase (ST) tagged with a vesicular stomatitis virus G
protein epitope that can readily be detected with the monoclonal antibody ‘P5D4’.
The tagged ST has previously been shown by EM to localize predominantly to the
TGN [98]. In SA48 cells, Hrs showed only limited co-localization with the TGN
marker, and the majority of Hrs was on tubular-vesicular membranes located some
distance away from the labeled TGN (Figure 14 C), suggesting that these membranes
were not part of the TGN.
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Figure 14. Double labeling experiments with anti-Hrs or anti-Aip1/Alix with anti-Tfr,
P5D4-tagged sialyl-transferase (ST) and anti-CD63.
(A) and (B) Primary macrophages were fed with 5nm BSA gold (arrowheads) for 30 min
followed by a 30 min chase period. The sections were then double-labeled with anti-Hrs
(10nm gold, arrows) and anti-Tfr (15nm gold, not indicated). Both images show several oval-
shaped dense structures (OD) filled with internalized BSA gold that are also labeled with both
antibodies. Co-localization of Hrs and Tfr is also found on the tubular vesicular membranes
next to the late endocytic structures. In (C) SA48 HeLa cells were double-labeled with the
P5D4 monoclonal antibody (15nm gold, representing ST tagged with the VSV-G epitope) and
anti-Hrs (10nm gold, arrows). Note that Hrs is found apposed to the TGN-region but shows
only limited co-localization with ST. (D) and (E) show two typical MVBs in MT4 cells that
were fed for 40 min with 5nm BSA gold (arrowheads). (D) Double-labeling for Hrs (10 nm
gold) and CD63 (15nm gold). In (E) the section was double-labeled with anti-Tfr (10nm) and
anti-Aip1/Alix (15nm) showing that membranes close to the MVB, but not the MVB itself are
labeled for both proteins. The large arrowhead in (D) indicates labeled membranes continuous
with the MVB. G-Golgi complex. Bars-100nm
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We found a very similar labeling pattern for Tsg101, Aip1/Alix (Figure 15 A-
D) and Vps4B (not shown) with the exception that these three proteins were more
associated with late endocytic structures. Significant labeling for Tsg101 and
Aip1/Alix was found on late endosomes (Figure 15 B and D), but the labeling was
more frequently detected on the tubular-vesicular membranes located between late
endosomes and the Golgi stack (Figure 15 A, B and C). We also used MT4 cells to
determine whether ESCRT specifically localized to MVBs. As described above, after
40 min. of incubation with 5nm BSA gold, MVBs but not late endosomes/lysosomes
were filled with BSA gold in these cells and this condition was therefore used to
localize ESCRT. All four antibodies displayed only low labeling on gold-filled
MVBs; instead the labeling for ESCRT was more often associated with membranes
close to or in continuity with MVBs rather than MVBs themselves (see figure 14 D
and E).
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Figure 15: Localization of Aip-1/Alix and Tsg101 in primary macrophages.
In all images primary macrophages were fed with 16 nm and 5 nm BSA-gold (5nm gold
is indicated with arrowheads in (A) and (C)) as described in figure 8 E. (A), (C) and (D)
Sections labeled with anti-Aip-1/Alix (10nm gold, arrows). (A) shows an extended region
with one oval-shaped dense structure (OD) and several late endosomes/lysosomes (LE),
closely apposed to a Golgi stack (G). Aip1/Alix was found on the endosomes as well as
on tubular-vesicular membranes next to the late endosomes and the Golgi complex. In (B)
the section was labeled with anti-Tsg101 (10nm gold arrows) and shows oval-shaped
dense structures (OD) close to a Golgi stack (G). Labeling was seen on the dense
structures as well as on tubular vesicular membranes closely apposed to these structures.
(C) Endosomal vesicles, most likely of early endocytic origin (internalized 5nm gold
indicated with arrowheads), labeled with Aip-1/Alix. (D) An oval-shaped dense structure
labeled with anti-Aip-1/Alix closely apposed to a Golgi stack (G). Nu-nucleus. Bars-
100nm.  
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Our observations suggested that Hrs localizes predominantly to the early
endocytic pathway, while the other three proteins were preferentially associated with
domains of late endocytic compartments. To confirm this qualitative impression, we
quantified the relative distribution of Hrs and Aip1/Alix over different intracellular
membranes in both macrophages and MT4 cells (Table 3). This confirmed that the
majority of Hrs was associated with the early endocytic pathway, representing 34-
38% of the total labeling. For Aip1/Alix only 10-20% of the label was on early
endocytic membranes, whereas 35-40% was associated with late endocytic
compartments.
MT4 macrophages
cellular structure (%) Hrs1 (%) Aip1/Alix (%) Hrs (%)
Aip1/Alix
plasma membrane 17.2 19.5 7.1 6
early endosome 8.2 1.6 13.5 8.7
early endosome
associated
26.2 7.9 24.8 10.5
total early endosome2 34.4 9.5 38.3 19.2
late endosome 1.6 8.8 5.4 13.3
late endosome associated 8.8 26.5 13.5 26.2
total late endosome2 10.4 35.3 18.9 39.5
MVB 1.8 2.9 n/d3 n/d3
TGN 3.6 2 4.7 3.9
mitochondria 6.6 6.8 5.3 6
ER/nuclear envelope 5.8 5.9 4.5 2.8
cytosol 12.7 12.8 9.6 9.2
unidentified membranes 7.6 5.4 4 5.9
Table 3. Intra-cellular distribution of Hrs and Aip1/Alix in MT4 cells and human
macrophages.
1 On two different grids from two different labeling experiments, with either anti-Hrs or anti-
Aip1/Alix, a total of 200 gold particles per grid were allocated to the cellular structures
indicated on the left. In the case of MT4, cells were fed for 40 min with 5nm BSA-gold as
described in the text. Quantification in macrophages was done on cells fed with 16nm and
5nm BSA-gold as described in figure 8E. The numbers were obtained by dividing the number
of gold particles found on each cellular structure by the total gold particles counted.
2 Total early/late endosome is the sum of the percentage on early/late endosomes and on
membranes associated with early/late endosomes.
3 n/d: no MVBs were detected in sections of primary human macrophages.
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3.1.7 HIV-1 infection does not alter ESCRT localization
Analysis of uninfected T-cells and macrophages revealed that proteins of the
ESCRT machinery were enriched at the proposed site of HIV budding, the plasma
membrane of T cells and endosomes in macrophages, respectively (see figure 9). This
suggested that the endogenous ESCRT pool located at the respective proposed site of
budding may suffice for HIV-budding and that this complex might not be recruited to
the site of HIV release. All three cell types, MT4 cells, primary human CD4+ T cells
and macrophages were therefore infected with HIV-1, and ESCRT proteins were
quantified as described above. Infected cells were identified based on their labeling
with an antibody against the HIV-1 CA protein and by detection of typical budding
profiles and virus particles (for an example, see figure 17 A-F). The MT4 cell line
was particularly useful for this quantitative analysis as these cells express high levels
of viral antigen and exhibit many budding profiles at the cell surface (Figure 17 B-D).
Thus, a redistribution of ESCRT proteins should be easily seen in these cells.
Quantification of antibody labeling to ESCRT proteins showed, however, that
HIV-1 infection did not affect the intracellular distribution of ESCRT in any of the
three cell-types (Figure 16 A-C, compare to Figure 9 A-C). The percentage of
labeling attributed to either the plasma membrane or endosomes (representing the
membranes relevant for HIV-1 budding in T cells and macrophages, respectively) was
directly compared in uninfected and infected cells (Figure 16D). This comparison
revealed that the relative amount of labeling for each of the four antigens increased or
decreased by only 1-6%.
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Figure 16: Quantification of the localization of ESCRTsubunits in HIV-1 infected cells
by EM.
Thawed cryosections of HIV-1-infected (A) MT4 cells, (B) Primary human CD4+
lymphocytes and (C) Primary human macrophages were labeled with the same antibodies and
subjected to the same quantification procedure as described in figure 9. The data in primary T
cells and macrophages represent the average of values obtained from two different donors in
infected cells. (D) Increase or decrease of ESCRT labeling on the plasma membrane and
endosomes of uninfected and infected cells. Values represent relative labeling of the plasma
membrane and endosomes in infected cells (figure 16A-C) minus labeling in uninfected cells
(figure 9A-C) on the same two compartments.
Importantly, all four antibodies labeled HIV-1 budding profiles (Figure 17 C,
D, and data not shown) and extracellular virions (Figure 16 A-C). This confirmed a
previous study, biochemically showing incorporation Tsg101, Aip1/Alix and Vps4B
into virus particles [50]. Thus, although ESCRT subunits were incorporated into
budding virions, we could not provide any evidence that they were specifically
enriched at, or relocated to, the site of virus budding. This suggested that on those
membranes that are relevant for HIV-1 budding the endogenous pool of ESCRT is
sufficient for virus release.
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Figure 17: HIV-1 budding in T cells and macrophages.
(A, B) Cryosections of HIV-1-infected primary T cells (A) or MT4 cells (B) showing HIV
budding profiles and virus particles at the cell surface labeled with anti-CA and next to a
clathrin coated pit (arrow). (C, D) Cryosections of infected MT4 cells labeled with anti-Hrs
(C) or anti-Tsg101 (D). (E, F) Cryosections of HIV-1-infected primary macrophages showing
virus particles and putative budding profiles (arrowheads) labeled with anti-CA. Bars-200nm
(A-D), 100nm (E, F).
HIV-1 was previously proposed to bud primarily on the plasma membrane of
T cells and on endosomes in macrophages (see below). Therefore, the differential
distribution of ESCRT subunits in T cells and macrophages suggested that ESCRT
localization determined the site of HIV-1 budding in these two cell types. In
agreement with this, we found that in MT4 cells and in primary T cells budding
profiles localized almost exclusively to the cell surface (Figure 17 A-D), frequently
next to clathrin-coated pits (Figure 17 B, arrow). In contrast, the site of HIV-1
budding in macrophages was more difficult to determine (figure 17 E, F). Virus
particles and viral budding profiles were frequently found on membranes that could
not unequivocally be assigned to either the cell surface or endosomes of macrophages
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(Figure 16 E, F). Therefore, the site of HIV budding in macrophages was
characterized in detail in the second part of this work.
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3.2 HIV-1 budding in primary human macrophages
During our above described analysis of HIV-1 infected T lymphocytes and
macrophages by immuno EM, we qualitatively observed that in macrophages, virus
particles accumulated in the extracellular space (as in T cells) as well as in
cytoplasmic vacuolar structures (Figure 17 E, F). Budding also seemed to occur from
both the cell surface and vacuolar membranes in these cells. Localization of viral
structures to the cell surface of macrophages was unexpected, since earlier studies
showed that HIV-1 particles predominantly accumulated in intracellular
compartments of monocytes/macrophages [18, 20-27]. Two widely recognized recent
studies suggested that this intracellular compartment was of endocytic origin [28, 29].
In the latter studies, it was proposed that in macrophages HIV-1 budded and
accumulated in late endosomes from where the virus could be released into the
extracellular environment via exocytosis. This obvious discrepancy with our
observations prompted us to study the site of HIV budding and accumulation in
macrophages in detail.
3.2.1 HIV-1 budding structures and particles are found on the cell surface and in
intracellular vacuoles
To characterize budding and release of HIV-1 in detail by electron microscopy
(EM), cultures of primary human macrophages were infected with either of the
macrophage-tropic HIV-1 strains Ba-L or YU-2 [101]. Virus release into the culture
supernatant was monitored by p24 ELISA and cells were fixed when the p24 values
in the supernatant had reached a plateau, typically around 12 to 17 days post-
infection (data not shown). Cells were then fixed and either processed for immuno-
EM or embedded in epoxy resin (Epon). To get an overview of macrophage
morphology and localization of virus particles and budding sites, Epon embedded
samples were first examined. Epon embedded sections allow morphology-based
identification of electron dense virus particles without further treatment such as
immunolabeling. Therefore, 60 nm Epon sections were contrasted with lead citrate
and examined by EM (Figure 18).  In agreement with earlier studies, we found that
macrophage profiles had diameters of around 20 to 50µm and a rather complex
morphology with many cell surface protrusions, resembling lamellipodia or filopodia,
and large cytoplasmic vacuolar structures (Figure 18 D, [24]). Early and late budding
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profiles of HIV-1 were identified as typical crescent-shaped or round electron dense
structures, respectively (Figure 18 A-C, arrowheads). This electron dense ‘shell’ most
likely represented the main structural HIV-1 Gag protein. HIV-1 buds were seen both
intracellularly (Figure 18A, B) and at the cell surface (Figure 18C). Immature and
mature HIV-1 particles were also found both at the cell surface (Figure 18F) and in
vacuolar structures (Figure 18E) and could be easily identified by their electron dense
Gag shell or conical cores, respectively (Figure 18 E, F).
Figure 18: Overview of macrophage morphology and HIV localization in Epon-
embedded samples.
Epon sections of primary human macrophages 17 days after infection with the HIV-1 Ba-L
strain. (A) Vertical section through an infected macrophage. The flat bottom of the cell is in
the left lower corner. (B) Magnification of the boxed area in (A), showing a vacuolar
structure containing filopodia-like protrusions and three HIV-1 budding structures
(arrowheads). (C) Typical cell surface organization of macrophages, displaying many long
filopodia-like protrusions. On the cell surface several HIV-1 budding sites (arrowheads) are
found. (D) Horizontal section through an infected macrophage with one or several large virus-
filled structures. (E) Section through a large vacuole filled with mature virus particles. The
small vacuolar structure contains an early virus bud (arrowhead). (F) Mature virions
accumulating on the cell surface. Bars- 2µm (A, D), 1 µm (C, E, F), 200nm (B).
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Epon sections are, however, not suitable for immuno labeling with antibodies.
Thus, we next used immuno EM to identify viral structures based on their antibody
labeling to extend our qualitative observations. Thawed 60 nm cryosections were
labeled with an antibody to the viral Capsid (CA) protein to identify infected cells and
virus particles. In agreement with the studies of Pelchen-Matthews et al. and Raposo
et al. [28, 29], anti-CA labeled HIV particles were readily detected in large vacuoles,
seemingly representing an intracellular compartment (Figure 19 A, B). Although the
conical cores of mature HIV-1 particles were generally not detected in cryosections,
mature virions could easily be identified by the lack of an electron-dense Gag shell.
We noted that the limiting membranes of virus-containing vacuoles were often open
to the extracellular space and resembled deep plasma membrane invaginations instead
(Figure 19 C and F). The virus-filled vacuoles furthermore contained slender
membrane protrusions, resembling lamellipodia of the cell surface (Figure 19 D).
Finally, on their limiting membrane we frequently observed clathrin-coated pits
(Figure 19 E, arrowhead), an endocytic structure that is unique to the plasma
membrane. Thus it collectively appeared that at least a subset of the membranes
enclosing the budded virions was plasma membrane-derived.
Whereas virus particles were readily seen on cryo-sections, budding profiles
were much more rare (see below) and were seen on the vacuolar membranes (Figure
20 A) as well as on the plasma membrane (Figure 20 B-E; [30]. On both sets of
membranes budding profiles often occurred next to clathrin-coated pits (Figure 20 A,
B, E; arrowheads), again indicating that the limiting vacuolar membrane in such
examples was cell surface derived.
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Figure 19. A gallery of primary human macrophages infected with HIV-1 strains YU-2
and Ba-L.
Primary human macrophages were infected with HIV-1 strain YU-2 (A, D, F) or Ba-L (B, C,
E). Thawed cryosections were labeled with anti-Capsid antibody followed by 10nm (A-D, F)
or 5nm (E) protein A gold. (A) and (B): labeled virions of both HIV-1 strains accumulate in
identical looking vacuolar structures. With both strains, labeled virus is also found in plasma
membrane invaginations that are directly connected to the extracellular space (C, F) or in
vacuolar structures filled with filopodia-like protrusions (D). (E), a virus-containing vacuolar
structure with a clathrin coated pit (arrowhead). Bar-100 nm.
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Figure 20. A gallery of budding profiles in primary human macrophages infected with
HIV-1 strains YU-2 and Ba-L.
Primary human macrophages were infected with HIV-1 strain YU-2 (A, C, E) or Ba-L (B, D).
Thawed cryosections were labeled with anti-Capsid antibody followed by 5nm (A) or 10nm
(B-E) protein A gold. Virus budding profiles were found inside vacuolar structures (A) or on
the cell surface (B- E). In (A, B, E), budding profiles are next to a clathrin coated pit
(arrowheads). Bar-100 nm.
Sections of YU-2 and Ba-L infected macrophages were indistinguishable; with
both strains viruses were seen to accumulate in vacuolar structures and budding
profiles occurred both at the plasma membrane and at the vacuolar membrane.
Replication kinetics for both virus strains were assayed by p24 ELISA and were
similar ([100], data not shown). Generally, differences between samples, for instance
in the percentage of infected cells, could be attributed to donor variability rather than
to difference between the two virus strains (not shown). Throughout the remainder of
this study we therefore focused on Ba-L infected macrophages only.
Collectively, we confirmed that in primary human macrophages HIV-1
particles bud into and accumulate in large vacuoles. However, whereas these HIV-1
filled vacuoles were previously proposed to be part of the endocytic pathway [28, 29],
we found that at least a subset showed hallmarks of the plasma membrane.
3.2.2 BSA gold-uptake and Ruthenium Red stain to discriminate plasma
membrane from endocytic compartments.
We next set out to define the plasma membrane and endosomes in primary
macrophages. Our attempts to unequivocally discriminate cell surface and endosomal
membranes by using immuno EM and antibodies directed against membrane marker
proteins failed. We found that most, if not all, endosomal marker proteins were
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distributed over several membranes of the endocytic pathway, including the plasma
membrane (see section 3.2.4). Therefore, we decided to make use of a marker
independent assay to discriminate endosomal membranes and the plasma membrane
of macrophages. This assay is based on sequential marking of endosomes (by
endocytic uptake of BSA gold beads) and the plasma membrane (by cell surface
staining upon fixation) and was first established in uninfected macrophages.
Macrophages were starved in serum-free medium over night and incubated
with BSA coupled to 10nm gold particles (BSA gold). At 37° C, BSA gold is readily
taken up by fluid phase endocytosis and therefore marks the endocytic pathway. As
shown in chapter 3.1.2, endocytic BSA gold uptake for 2 hrs before fixing leads to
filling of at least 75% of all endocytic compartments including late
endosomes/lysosomes in primary macrophages. After incubation for 2 hrs, the gold-
filled cells were placed on ice to shut down their endocytic activity, washed well to
remove excess BSA gold from the cell surface and fixed on ice in the presence of the
cell surface stain Ruthenium Red (RR). RR is a membrane-impermeable compound
that binds to the cell surface via carbohydrate moieties [108, 109]. Because of its
small size, RR can readily penetrate into very small and slender membrane cavities at
the cell surface [117], whereas fixation at 4°C prevented its internalization into
endosomes. Upon post-fixation with osmium tetroxide (OsO4), RR and OsO4 form an
electron-dense precipitate that is readily seen on Epon embedded sections [106, 107].
The RR-stain revealed an unexpected complex plasma membrane organization
of macrophages (Figure 21); at low magnification the RR stain highlighted many
finger-like protrusions at the cell surface (Figure 21 A, B and D). Filopodia from two
neighboring cells often formed tight-fitting contact zones (Figure 21 A, arrows) where
the RR stain was more electron dense than on single lipid bilayers. The RR-stain also
decorated the limiting membrane of large vacuolar structures that were heterogeneous
in size and shape (Figure 21 A-F). These contained a complex collection of RR-
positive membranes, often resembling plasma membrane filopodia (Figure 21 D, E).
Because on sections the RR-stained membranes appeared ‘closed’ and were often
found in the peri-nuclear region (Figure 21 C, F), they could readily be mistaken for
an intracellular compartment. We noted that a subset of identical looking vacuoles
was not stained with RR (Figure 21 E). Since these were never filled with internalized
BSA gold, they were obviously not of endocytic origin. Their failure to stain with RR
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suggested that they were not directly connected to the cell surface or that they were
inaccessible to RR for technical reasons. We noticed, for instance, that the plasma
membrane and vacuoles located on the bottom of the cells that was attached to the
substrate were not efficiently stained with RR.
BSA gold-filled endosomes (Figure 21 C, E) were always devoid of RR and
were typically round or oval-shaped, rather homogenous in size, and significantly
smaller than the RR-stained vacuoles. Finally, all other cellular structures such as the
Golgi complex or the endoplasmic reticulum were neither labeled with RR nor filled
with BSA-gold.
Collectively, the BSA-gold uptake and RR-stain enabled us to discriminate
cell surface-derived membranes from endocytic compartments. The RR stain also
revealed that human primary macrophages cultured in vitro display a complex plasma
membrane organization, consisting of many protrusions and invaginations. The latter
often resembled profiles of intracellular vacuoles on thin sections.
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Figure 21. Ruthenium red staining of uninfected macrophages reveals a complex plasma
membrane organization.
Primary macrophages were fed for 2 hrs with BSA gold particles, fixed on ice in the presence
of Ruthenium Red (RR) and embedded in Epon. (A) Two cell profiles contacting each other,
showing the organization of the RR-stained cell surface with many protrusions and RR-
positive, seemingly intracellular, vacuolar structures close to the nucleus (Nu). At the tight-
fitting contact zones between two cells (arrows) the stain appears more electron-dense than on
single lipid bilayers. (B) Higher magnification of the boxed area in (A). It shows the
collection of vacuolar structures stained with RR. (C) A higher magnification of the boxed
area in (B) showing a RR-positive vacuole next to a BSA-gold filled endosome (arrowhead).
(D) Shows a cell profile with many RR-positive filopodia at the cell surface. It also shows an
area with RR-positive filopodia that appear intracellular in this section. Note that the BSA
gold-filled endosomes (arrowheads) are significantly smaller than the vacuolar structures and
that vacuoles have no internalized BSA gold. (E) Two filopodia-containing vacuolar
structures. In the upper one the membranes are not RR stained, indicating that not all vacuoles
are connected to the cell surface and accessible to the stain. (F) A collection of BSA gold-
filled endosomes (arrowheads) next to RR-stained vacuolar structures. Bar-2µm (A, B),
500nm (C-F).
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3.2.3 HIV-1 budding occurs on cell surface-derived membranes.
The RR-staining and BSA gold uptake method was next used to identify the
origin of the membranes from which HIV-1 budded and that enclosed budded virions
in primary human macrophages. Macrophages were differentiated in vitro for one
week and infected with the macrophage-tropic HIV-1 Ba-L strain. As before,
replication kinetics were evaluated by measuring HIV-1 CA amounts in the culture
supernatants by ELISA, and cells were fixed and processed for EM at days 12 and 17
post infection (Figure 22A).
Figure 22: Overview of the experimental setup to discriminate plasma membrane and
endosomes in infected macrophages.
Macrophages were infected with HIV-1 Ba-L and treated as described in Materials and
Methods. (A) A flow diagram of the time course of macrophage differentiation, infection and
processing for EM. (B) A cell profile of an infected macrophage at low magnification
displaying a complex RR-stained plasma membrane organization and RR stained vacuolar
structures (arrows) that contain virus particles. Bar-2µm.
As seen before in uninfected cells, cell profiles of Epon-embedded infected
macrophages displayed complex RR-stained membrane structures, including
numerous surface protrusions, invaginations and RR-positive vacuolar structures
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(Figure 22 B, arrows), often filled with mature virus particles with a typical conical
core, (23 A-C, E, F). These virus-filled vacuoles were devoid of BSA gold whereas
their limiting membrane and the surface of the virions they enclosed, were stained
with RR (Figure 22 B, C; 23 A-C, E, F), clearly showing that they were directly
connected to the cell surface. We also noted that many of the RR-positive virus-
containing vacuoles contained plasma membrane-like filopodia (Figure 23 C, J) and
that their limiting membrane displayed clathrin-coated pits (Figure 23 E, F, arrows),
supporting the fact that they were cell surface-derived.
Consistent with the RR-staining of uninfected macrophages, we found that not
all virus-containing vacuoles were stained with RR (see, for instance, Figure 23 J).
Such RR-negative vacuoles did not contain BSA-gold excluding the possibility that
they were part of the endocytic pathway (Figure 23 J). Instead, gold-filled endosomes
appeared significantly smaller, more homogenous in size and never contained virus
particles (Figure 23 B, D, E, G, and K, arrowheads).
To substantiate this obvious size difference, we estimated the average profile
area of the virus-filled vacuoles and BSA gold-filled endosomes in cells of three
individual blood donors (Figure 24 A). The average profile area of gold-filled
endosomes was only 0.08µm2, corresponding to an average diameter of 0.28µm. This
value corresponded well to previously published data on the size of the central
vesicular elements of endosomes [84]. In contrast, the average profile area of virus-
filled vacuoles was 10 to 60 times bigger, between 1 and 3.1µm2 (Figure 24A).
Strikingly, this value corresponded well to the size of HIV-containing vacuoles
observed in previous studies (Figure 24A; [28, 29]. Whereas in the latter studies the
virus-filled vacuoles were suggested to be of endocytic origin, our data now indicate
that they are identical to RR-stained vacuoles representing plasma membrane
invaginations.
Budding profiles were either found on the cell surface (Figure 23 H) or on
RR-positive (Figure 23 I) and RR-negative vacuolar-like membranes (Figure 23 J, K).
They were furthermore found on the tip of filopodia-like protrusions, frequently
inside the vacuolar structures (Figure 23 J, arrow).
Chapter 3 – Results
80
Figure 23. HIV-1 buds into and accumulates in ruthenium red-stained domains.
Macrophages were infected with HIV-1 Ba-L and treated as described in figure 22 and in
Materials and Methods. (A) and (B) show virus-containing structures that are apparently
intra-cytoplasmic but are stained with RR. (C) Shows a collection of RR-stained filopodia
interspaced by RR- stained mature virus particles. In (D) a large vacuolar structure that is
directly connected to the RR-stained cell surface and contains numerous RR-stained virions.
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The inset shows a mature virus particle on the tip of a finger-like plasma membrane
protrusion. (E) and (F) are two RR-stained vacuolar structures that contain virus particles and
that display clathrin-coated pits (arrows). The arrowheads indicate gold-filled endosomes that
are not RR-stained. (G) RR-stained virus particles that accumulate between the plasma
membranes of two neighboring cells. Arrowheads indicate BSA gold-filled endosomes
without RR stain. (H) to (K) Budding profiles are found on the RR-stained cell surface (H),
on RR-stained vacuolar structures (I) or on vacuolar structures that are devoid of RR and
BSA gold (J, K). The arrow in (J) indicates an early viral bud on the tip of a finger-like
protrusion. Arrowheads in (K) mark BSA gold-filled endosomes. Nu- nucleus. Bar-200nm
(A, B), 2µm (D), 500nm (C, E-K).
Our qualitative observations of the localization of viral structures (as depicted
in figure 23) were next analyzed in a quantitative manner (Figure 24 B). To this end,
cells from three different donors were analyzed. Free virus particles and budding sites
were assigned to either of three categories, i) on RR positive, BSA gold negative
membranes (RR+ BSA gold-), ii) on membranes without both markers (RR- BSA
gold-) and iii) on membranes lacking RR but with the endocytic marker (RR- BSA
gold+). This quantification revealed that over 94% of all viral structures were found
on RR stained membranes or in vacuolar structures that were devoid of internalized
gold and that were in the majority of the cases stained with RR (Figure 24 B). Only
few viral structures were seen in vacuoles containing BSA gold. As mentioned above,
the number of free virus particles largely exceeded the number of budding profiles
and 91 to 97% of the viral structures was immature or mature virus (Figure 24 B). We
nevertheless quantified budding profiles seen over the above-mentioned membrane
types in macrophages derived from the same three donors (Figure 24 C). Virtually all
of the budding profiles (98-100%) were counted on the RR stained cell surface or on
vacuolar membranes that were either RR-positive or RR-negative (but were
morphologically indistinguishable) and were devoid of internalized gold (Figure 24
C). We also found two budding profiles on structures that contained BSA-gold (one
event each for donor 1 and 3). However, in these two examples the gold-containing
structures did not look like typical endosomes and their gold-content likely resulted
from an incomplete wash-off of the fluid phase marker from the cell surface.
These data strikingly show that in primary human macrophages, HIV-1
budding occurs predominantly on cell surface derived membranes rather than on
endosomal membranes.
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Figure 24: Quantification of the membrane compartments where HIV-1 accumulates
and buds.
Infected macrophages were infected and processed as described in figure 22. (A)
Quantification of the average profile area of virus containing vacuoles and BSA gold-filled
endosomes. The average profile area of virus-filled vacuoles in the left panel is based on the
images of figure 1A,B; 2A; 3A-C in the publication by Raposo et al., the figure 3A-D; 4A,B;
5A; 6A-C; 7A in Pelchen-Matthews et al. These two studies used cryo-sections of infected
macrophages only. The values Donor 1 to Donor 3 therefore represent the average area
covered by virus-filled vacuoles or gold-filled endosomes estimated on cryo-sections of
infected macrophages from three donors. The size was estimated in at least 10 electron
micrographs per donor using standard stereological methods. For estimation of endosome
size, clearly identifiable endosomal profiles, abundantly filled with BSA-gold were
considered. Error bars denote standard error of the mean. (B) Quantification of the percentage
of free virus particles and budding profiles in infected macrophages prepared from the same
three blood donors as in (A), but embedded in Epon. Three types of cellular membranes that
either surrounded free virus or that displayed budding sites were considered: 1. RR-positive
without internalized BSA gold (RR+, BSA gold-), 2. RR-negative without BSA gold (RR-,
BSA gold-) and 3. RR-negative with BSA gold (RR-, BSA gold+). ‘Free virus’ included
mature virions with a typical conical core and immature particles displaying an electron dense
Gag shell. ‘Budding sites’ included ‘late buds’ consisting of spherical profiles that are
connected to a membrane via a stalk (see, for instance figure (23 K)) and ‘early buds’, half-
moon-shaped membrane profiles with an electron-dense (Gag) shell on their concave side
(see, for instance, figure 23 H). In (C) the distribution of budding profiles was quantified in
the same three donors as in (B).
3.2.4 HIV-1 particles acquire the late endosomal membrane proteins CD63 and
lamp-1 and the cell surface protein CD44.
Pelchen-Matthews et al. have previously demonstrated the incorporation of the
late endosomal marker proteins CD63 and lamp-1 into the HIV-1 envelope. This
incorporation was taken as important evidence that HIV-1 buds into endosomes in
primary human macrophages and was based on the assumption that CD63 and lamp-1
localized to late endosomes/lysosomes preferentially. Our data implied, however, that
HIV-1 buds predominantly at cell surface-derived membranes in these cells,
consistent with results showing that HIV-1 also acquires the cell surface protein
CD44 [118]. We therefore localized the late endosomal marker proteins CD63 and
lamp-1 as well as the cell surface protein CD44 in infected macrophages by EM.
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Figure 25: Localization of the late endosomal/ lysosomal markers CD63 and lamp-1.
Primary human macrophages were infected with HIV-1 strain Ba-L and fed with BSA
coupled to 10 nm gold. Thawed cryosections were labeled with mouse monoclonal antibodies
to endosomal/lysosomal membrane markers followed by rabbit anti-mouse IgG and 15nm
protein A gold (A-C) or double-labeled with the same membrane markers and rabbit anti-
Capsid antibody followed by 5nm protein A gold. (D-I). (A) to (C) Thawed cryosections were
labeled with anti-CD63, followed by rabbit anti-mouse IgG and 15nm protein A gold. In (A)
and (B), anti-CD63 localizes to BSA-gold-filled endosomes (arrowheads) and the tubular
vesicular membranes nearby. In (C) CD63 localizes to extended regions of the plasma
membranes of two adjacent macrophages. (D) and (E) show anti-CD63 positive budding
profiles at the cell surface that are also labeled with anti-Capsid (5nm). (F, G) CD63 is
efficiently incorporated into the envelope of virus particles that accumulate in vacuolar
structures and also localizes to BSA gold-filled endosomes (arrowheads in (F)). Note that the
limiting vacuolar membrane in (G) is decorated with a clathrin-coated pit (arrow). (H, I)
Thawed cryosections were double-labeled with anti-lamp-1 followed by 15nm protein A gold
and anti-CA followed by 5nm protein A gold. Lamp-1 localizes to BSA gold-filled
endosomes (arrows in H) and the tubular-vesicular membranes nearby and is incorporated at
low levels into viral particles (H, I). Bar-100nm
First, cryosections of infected macrophages were labeled with antibodies to
CD63 or lamp-1. Examination of these cryosections revealed that both proteins did
not only localize to BSA gold-filled endosomes and the tubular-vesicular membranes
nearby (Figure 25 A, B and H), but also to the plasma membrane (Figure 25 C and E
and not shown). Typically, cells contained large plasma membrane patches where
CD63 seemed highly concentrated as well as regions that had less CD63 labeling (not
shown). We also found that the virus incorporated CD63 during budding at the
plasma membrane (Figure 25 D, E). Extracellular viruses (not shown) as well as
virions inside vacuolar structures were significantly labeled with anti-CD63 (Figure
25 F, G) and to a lesser extent with lamp-1 (Figure 25 H, I). Thus, under our infection
conditions these late endosomal/lysosomal proteins were also incorporated into
virions.
Immunolabeling of thawed cryosections with anti-CD44 revealed that this
protein localized almost exclusively to the cell surface (Figure 26 A) and was not
present at all on BSA gold-filled endosomes (Figure 26 A, C; arrowheads). Budding
profiles on vacuolar structures (Figure 26 B) as well as virus particles (Figure 26 C)
were decorated with the cell surface protein CD44, further evidencing that HIV-1
budding occurred on the cell surface.
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Thus, although HIV-1 buds predominantly at cell surface derived membranes,
the virus not only incorporates plasma membrane proteins such as CD44 but also
readily incorporates endosomal/lysosomal proteins such as CD63 and lamp-1.
Figure 26: Localization of the cell surface protein CD44.
Primary human macrophages were infected with HIV-1 strain Ba-L and fed with BSA
coupled to 10 nm gold (except in (B)). Thawed cryosections were labeled with a mouse
monoclonal antibody to CD44 followed by rabbit anti-mouse IgG and 15nm (A, C) or 10nm
protein A gold (B). In (B) and (C), sections were double-labeled with anti-CD44 and rabbit
anti-Capsid antibody followed by 5nm protein A gold. In (A), CD44 localizes to the cell
surface, especially to filopodia-like membrane protrusions, but is absent from BSA gold-filled
endosomes (arrowhead). (B) Shows a set of membranes displaying a late budding profile and
virus particles decorated with anti-CD44 and anti-CA. (C) Shows a large intracellular vacuole
containing numerous virus particles which are labeled with anti-CD44. Note that the BSA
gold-filled endosomes (arrowheads) are devoid of anti-CD44 labeling. Bars- 100 nm
The distribution of CD63 and CD44 over different membranes was next
analyzed in a quantitative manner by estimating the labeling density of these markers
on late endosomes, on the cell surface and on the limiting membrane of the virus-
filled vacuolar structures in cells from three different donors (Figure 27). We also
included virions in this quantification since we expected the labeling density on virus
particles to resemble the one of the plasma membrane. Quantification showed that
both in uninfected and infected macrophages, significant amounts of CD63 localized
to the cell surface (Figure 27), confirming our qualitative observations. Depending on
the donor, the labeling density on BSA gold-filled late endosomes was around three
times higher compared to the cell surface (Figure 27). On the vacuolar membranes
surrounding the viruses the density was similar to the plasma membrane, providing
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additional evidence for its plasma membrane-, rather than endocytic, origin. We
unexpectedly found that the labeling density on the viral envelope was intermediate
between the plasma membrane and endosomes (Figure 27). This suggested that HIV
budded preferentially from plasma membrane regions that concentrated CD63.
However, although we readily found budding profiles at the cell surface that were
labeled with CD63 (Figure 25 D, E) and lamp-1 (not shown), we did not find any
evidence that budding occurred from those regions that were significantly enriched in
CD63 (see Discussion).
When CD44 was quantified in a similar way, we found that this protein
localized predominantly to the cell surface, with very low labeling on endosomes
(Figure 27, right panel). Importantly, the labeling density of this protein on the viral
envelope and on the virus-filled vacuolar membrane was identical to the one of the
plasma membrane (Figure 27, right panel). These results additionally confirm that
HIV-1 buds from the cell surface and that the limiting membrane of the vacuolar
structures is plasma membrane-derived.
Chapter 3 – Results
88
Figure 27: Quantification of CD63 and CD44 on different cellular membranes and on
virus particles.
The labeling densities for CD63 and CD44 were quantified on late endosomes and the cell
surface of uninfected and infected macrophages and additionally on virions and the limiting
membrane of virus-containing vacuolar structures in infected macrophages. The donors 1 to 3
are the same as those used in figure 24 to quantify the distribution of budded virions and
budding profiles. CD44 labeling density was determined in donor 1 only. The values
represent the average from two independent labeling experiments and two different grids per
experiment. At least 200 gold particles were counted per labeling experiment and donor.
Error bars denote standard error. The cell surface was defined as plasma membrane profiles
that were clearly external and ignoring intracellular membranes with plasma membrane-like
morphology. Late endosomes were identified by the presence of internalized BSA gold and
their typical morphology.
Our data thus confirm previous studies showing that HIV-1 incorporates both
endosomal and cell surface proteins into its envelope [118]. However, whereas it was
previously proposed that endosomal as well as cell surface proteins were incorporated
into the viral envelope during the budding process on endosomes, our collective data
show that HIV-1 budding occurs on the cell surface, where both types of proteins are
incorporated into virus particles. Collectively, our EM data provided strong evidence
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that HIV-1 buds on cell surface-derived membranes of primary human macrophages.
This is in contrast to previous studies [28, 29] and will be discussed below.
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Chapter 4
4. Discussion
4.1 Localization of ESCRT in T cells and macrophages
At the onset of this study T cells and macrophages, the two major target cell
types for HIV-1 infection, were believed to promote HIV-1 budding and release from
different membranes, the plasma membrane and endosomal membranes, respectively.
The cellular ESCRT complex was shown to be required for HIV-1 budding and
release in both cell types and it was therefore proposed that ESCRT was actively
recruited to the plasma membrane of T cells upon HIV-1 infection. However, a
detailed localization study of endogenous ESCRT proteins in HIV-1 susceptible cells
was not available before the onset of this study. We therefore localized four subunits
of the ESCRT machinery in detail by quantitative EM in uninfected and HIV-1
infected human T cells and macrophages. Our data contribute to the understanding of
ESCRT localization and function in these cells.
4.1.1 Membrane association of ESCRT proteins
Our analysis of ESCRT localization by quantitative EM showed that more
than 80% of ESCRT is associated with membrane structures. Previous studies
addressing the role of ESCRT in mammalian cells showed that the cellular ESCRT
machinery has several functional roles that involve interaction with membranes of the
endocytic pathway: First, targeting of ubiquitinated receptors to the intralumenal
vesicles of MVBs for subsequent degradation was shown to depend on ESCRT
function (reviewed in [51, 57]). Second, formation of the intralumenal MVB vesicles,
which is intimately linked to protein sorting to these vesicles, is believed to depend on
ESCRT function as well, although the mechanism of ESCRT action during this
process is not entirely clear. It was, however, shown that ATPase activity of the
ESCRT-associated protein Vps4 is required for MVB formation. In particular,
overexpression of the inactive form of Vps4 (dnVps4) led to formation of an aberrant
endosomal compartment (the mammalian class E compartment), believed to represent
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enlarged MVBs lacking internal vesicles [60]. Furthermore, knock-down of the
ESCRT-associated protein Aip1/Alix by RNA interference indicated that this protein
also plays a role in the formation of the internal endosomal membranes [119], as
originally proposed in yeast. Recent results suggested, however, that Aip1/Alix may
have additional functions such as endosome positioning and the organization of the
actin network [120].
Although these established functions for ESCRT involve interaction with
endosomal membranes, previous studies suggested that ESCRT proteins are mainly
found in the cytoplasm [69, 114, 116, 121]. In contrast to previous reports, this study
showed by electron microscopy that ESCRT proteins localize predominantly on
membrane structures with only a minor fraction in the cytoplasm. Previous studies
were predominantly based on the localization of overexpressed and tagged proteins by
light microscopy [63, 69, 122, 123], whereas we localized and quantified endogenous
protein in T cells and macrophages by EM. Importantly, we were able to reproduce
the reported diffuse localization pattern of ESCRT proteins by immunofluorescence
microscopy and suggest that the tubular-vesicular membranes, to which the majority
of ESCRT localized by EM, could be mis-interpreted as ‘cytoplasmic’ localization in
light microscopy analyses.
 Since we could formally exclude the possibility that cytosolic ESCRT
proteins were only poorly detected by EM compared to their membrane associated
forms, the fact that ESCRT was predominantly cytosolic by membrane flotation
indicated that ESCRT proteins are peripherally attached to membranes and that this
membrane association was lost upon mechanical cell lysis [114, 116, 121, 124]. This
idea was supported by the fact that overexpression of Vps4E228Q, reported in several
independent studies to recruit and lock ESCRT to membranes [60, 63, 114, 125], did
not affect the amount of ESCRT in the membrane fractions.
4.1.2 ESCRT localization throughout the endocytic pathway
Our detailed EM localization study of Hrs, Tsg101, Aip1/Alix and Vps4B
showed that ESCRT localizes throughout the endocytic pathway, including the
plasma membrane. Comparison of the distributions of the four proteins suggested,
however, that the relative subcellular distribution of ESCRT varied depending on the
cell type. Whereas in both T cells and macrophages the majority of ESCRT proteins
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was found on tubular-vesicular membranes associated with endosomes, the amounts
of ESCRT on the plasma membrane and on endosomes differed between the two cell
types. The relatively high amounts of ESCRT on endosomes of macrophages may
simply reflect their function as professional antigen-presenting cells. As such they
may need a more elaborate endosomal system, particularly equipped to carry out
processes such as antigen processing and subsequent presentation of processed
antigen at the cell surface, processes which involve endosomal protein sorting and
recycling.
Our results confirm a previous light microscopy study showing that the
localization of Hrs and Tsg101 only partially overlaps [124]. Whereas Aip1/Alix,
Tsg101 and Vps4B were preferentially associated with late endocytic structures, Hrs
localized mostly to early endosomes, confirming previous data [126]. We propose that
this difference reflects different functions of subunits of the ESCRT machinery. Hrs
has been predicted to bind to at least six different factors, most of which are
preferentially associated with the early endocytic pathway, suggesting that this protein
may have more than one function [127]. A significant, but lower amount of Hrs was
found on late endosomes, in particular on tubular-vesicular membranes associated
with late endosomes. This fraction of Hrs co-localized with Aip-1/Alix, Tsg101 and
Vps4B and it appears likely that this colocalization reflects a function of Hrs that
overlaps with the other ESCRT subunits.
4.1.3 ESCRT localization to tubular-vesicular endocytic membranes
Surprisingly, the amount of ESCRT on tubular-vesicular endosomal membranes was
significantly higher than on MVBs. Since ESCRT has been linked to the formation of
the intra-lumenal endosomal vesicles of MVBs, the predominant localization to
tubular-vesicular membranes was unexpected, raising the question about the function
of this pool of ESCRT. Based on morphological similarity [92, 128, 129] and labeling
for Tfr it seems likely that these tubular-vesicular endocytic membranes are involved
in endosomal recycling and/or sorting. Similar membrane appendages of endosomes
have been suggested to be the site of receptor/ligand uncoupling [128] and to be
involved in endosomal sorting [129]. Our data thus suggest that ESCRT may play a
role in protein sorting and recycling in addition to its known function in MVB
formation. An alternative possibility is that the pool of ESCRT on tubular-vesicular
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endosomal membranes represents unassembled ESCRT components that are rapidly
recruited into functional complexes to support MVB formation. In this scenario,
functional complexes may be present only transiently on MVBs and, accordingly,
ESCRT proteins do not significantly accumulate on MVBs themselves. Instead,
inactive (unassembled) ESCRT proteins may preferentially localize to tubular-
vesicular membranes, rather than being cytoplasmic. However, the expression of
ATPase-deficient Vps4, which is believed to trap assembled ESCRT complexes, did
not result in depletion and relocation of this ESCRT pool to enlarged endosomal
structures. The latter result suggested that ESCRT proteins found on tubular-vesicular
membranes associated with endosomes also represented (functional) ESCRT
complexes and that ESCRT-dependent sorting steps may occur on tubular-vesicular
membranes rather than MVBs. In this scenario, MVBs would play a minor role during
endosomal protein sorting. The latter would be in agreement with our observation
that, even upon close inspection of endosomes in BSA-gold pulse-chase experiments,
the endocytic pathway of primary human macrophages appeared to be almost devoid
of MVBs.
In conclusion, our collective data suggested an unexpected role for endosome-
associated tubular vesicular membranes in the function of ESCRT, most likely in
protein sorting and recycling in the endocytic pathway.
4.1.4 ESCRT proteins are not recruited to HIV-1 budding sites
HIV-1 infection of T cells or macrophages did not lead to a detectable re-
localization of ESCRT. This was in contrast to previous studies concluding that
ESCRT was recruited to the site of HIV budding. However, these studies were based
on Gag over-expression analyses [69]. It is likely that in this Gag over-expression
context, ESCRT does not suffice to support virus-like particle formation, leading to
the observed redistribution. Since infection did not result in a redistribution of ESCRT
to the site of budding, our data would argue that on those membranes that are relevant
for HIV-1 budding, the endogenous pool of ESCRT is sufficient for virus release. Our
data showed furthermore that ESCRT was enriched at those membranes presumed to
be the site of HIV budding in T cells and macrophages, the plasma membrane and
endosomes, respectively, suggesting that ESCRT plays a role in determining the site
of budding. However, recent studies make a direct role for ESCRT in HIV-Gag
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targeting to certain membranes unlikely, as Gag was shown to accumulate on
endosomes independently of the interaction of the p6 subunit of Gag with Tsg101
[130]. The collective evidence furthermore suggested that Gag may traffic through
endocytic compartments, even in cells where budding occurs at the cell surface [50,
131-133]. Although ESCRT is clearly required for the process of HIV-1 budding, the
collective data were more consistent with an indirect role for ESCRT in determining
the site of HIV budding in different cell types.
Our qualitative observations in infected T cells confirmed the plasma
membrane as predominant site of HIV budding. The complex morphology of
macrophages, however, made it difficult to identify the predominant site of virus
budding in these cells. Interestingly, almost no MVBs were found in macrophages,
arguing against a pivotal role of MVBs in both protein sorting and HIV-1 budding in
these cells.
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4.2 HIV-1 budding in macrophages
HIV-1 budding and release from human macrophages has gained much
interest in recent years for several reasons. Whereas it was previously believed that
HIV-1 buds from the plasma membrane of most cell types including monocytes and
macrophages [18, 30], several independent studies suggested that HIV-1 buds on
intracellular membranes and accumulates in an intracellular compartment of human
macrophages [20, 24, 26, 28, 29]. It was therefore proposed that this compartment of
HIV-1 infected macrophages comprised a reservoir of infectious virions that could be
disseminated to T cells upon contact [38]. Whereas earlier EM studies suggested that
this intracellular virus-filled compartment belonged to the Golgi network [20, 24], it
was recently proposed to be of late endocytic origin. This was mainly based on the
observation that HIV-1 particles acquired late endosomal proteins such as CD63,
lamp-1 [28] and major histocompatibility complex type II (MHC II) molecules [29].
Here, the morphology of primary human macrophages and the site of HIV-1 budding
and release was analyzed in detail, and our data have strong implications for our view
on budding, release and storage of HIV-1 in these cells.
4.2.1 Analysis of macrophage morphology
In this study, we analyzed primary human macrophages, derived by in vitro
differentiation from peripheral blood monocytes. Our EM analysis revealed that
macrophages cultured in vitro exhibit an unexpectedly complex plasma membrane
organization with many long protrusions and deep invaginations. Unexpectedly, a
variety of apparently intracellular large vacuolar structures were also found to be
delineated by the plasma membrane, since the cell surface stain Ruthenium red (RR)
highlighted many of these apparently intracellular vacuolar structures, besides the
‘obvious’ plasma membrane regions (regions delineating the cell borders). The fact
that the limiting membrane of these vacuolar structures often showed hallmarks of the
plasma membrane (filopodia-like protrusions and clathrin coated pits) provided
additional evidence for its cell surface origin. Importantly, we found that this complex
system of vacuolar structures was morphologically distinct and spatially separated
from the intracellular endosomal system of macrophages. The two sets of structures
could furthermore be distinguished by their disability or ability of endocytic BSA
gold uptake, respectively. Collectively, our data argued that the vacuolar structures
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were limited by a cell surface-derived membrane and were not of endocytic origin.
The combined use of BSA gold as an endocytic tracer molecule and RR as a cell
surface stain was especially useful for the analysis of macrophage morphology and
was more unambiguous compared to immuno EM using antibodies (see below).
4.2.2 HIV-1 particles bud and accumulate on cell-surface-derived membranes of
macrophages
Analysis of HIV-1 infected macrophages confirmed previously published data,
showing that most virus particles accumulated in large cytoplasmic vacuoles and that
the virus budded from the limiting membranes of these vacuolar structures [28, 29].
However, our collective data demonstrated that the virus-containing vacuoles and the
cell surface-derived vacuolar structures were identical. The vacuolar membrane (as
well as the envelopes of virus particles inside vacuoles) was accessible to RR,
indicating that it was derived from the plasma membrane. Furthermore, virus-filled
vacuolar structures failed to internalize BSA gold and showed the same hallmarks of
plasma membrane as the above mentioned vacuolar structures, long filopodia and
clathrin coated pits. Strikingly, the latter two features can also be seen in previous
studies  (Figures 2 A and 3 B from [29]; Figures 5 B, C; 6 A, C; 7 A, B from [28]),
but were not discussed in these studies. Thus, together with the fact that the size of the
vacuoles corresponded well to previous studies, it must be clear that the virus-filled
compartment observed in the present study is identical to the one previously
described.
HIV-1 budding sites were found to localize to the same vacuolar compartment
as virions. However, they were also frequently seen on the plasma membrane,
together with single or few virus particles. Whereas free virus particles in the
extracellular space are easily lost during sample preparation, the distribution of
budding profiles in EM sections should quantitatively reflect their distribution in
intact cells. Strikingly, EM quantification of budding profiles demonstrated that in
primary human macrophages HIV-1 buds at the cell surface and on plasma membrane
derived vacuolar membranes but never at BSA gold-filled endosomes.
Therefore, our ultra-structural analyses of both infected and uninfected
macrophages cultured in vitro contributed in an unexpected way to the proposed role
of these cells in HIV-1 persistence. The finding that HIV-1 budding occurs on the cell
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surface of macrophages raises the question whether the deep invaginations of the
plasma membrane may provide domains for HIV-1 to be stored and hidden. It was
previously shown that cultured human macrophages store infectious virus for weeks
or months [38]. Although this study proposed a model in which virus was stored in a
late endosomal compartment/ in MVBs, it did not exclude the possibility that this
storage compartment consisted of deep plasma membrane invaginations, e.g. on the
bottom of the cells. In fact, we frequently observed virus particles trapped in the space
between cells and the underlying substrate by EM, and this viral ‘reservoir’ could not
be removed by washing the cell monolayer [38]. Our data thus aids at explaining how
these cells could create pockets where the virus is stored and can be released
occasionally in small amounts. Although this scenario is not much different from the
exosome-release hypothesis, it is likely that the regulation of virus storage and release
may underlie an entirely different mechanism.
4.2.3 HIV-1 envelopes incorporate endosomal and cell surface proteins
Previous studies, which proposed that the vacuolar virus-containing
compartment of macrophages was of endocytic origin, were mostly based on the
finding that endosomal membrane markers were present on the surface of virus
particles [28, 29, 118]. Our study confirmed these data showing that HIV-1 particles
acquired cellular proteins that are used as markers for endosomal membranes and
plasma membrane [28, 29, 118, 132, 134-137]. However, in contrast to previous
studies, we provide evidence that these proteins, including the endosomal marker
proteins, are acquired at the cell surface.
Although demonstrated in several independent studies [28, 118, 138, 139], it is
unclear why the HIV-1 envelope incorporates a subset of cellular proteins. One
proposal is that HIV-1 buds at specialized membrane domains such as ‘lipid raft’
membrane microdomains [139-142]. In fact, is has been shown that the membrane
composition of HIV-1 envelopes resembles that of such microdomains and differs
from the overall composition of host cell membranes [143]. Whether this composition
reflects that of pre-existing microdomains in intact cellular membranes is, however,
unclear.
The fact that the labeling density of CD63 was higher in virions compared to
the plasma membrane, suggests that certain proteins are specifically enriched during
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the budding process. Such enrichment could be achieved by budding at specific
plasma membrane domains that concentrate or exclude cellular proteins, as recently
suggested [134]. However, although CD63 appeared highly concentrated in some
parts of the cell surface of macrophages, we could not find any evidence that the virus
preferentially budded from such domains. Whereas the significance of these CD63
cell surface patches for HIV-budding remains to be investigated, they may have
important implications for the use of anti-CD63 as a putative MVB-marker (see
below).
Collective evidence showed that the ESCRT machinery, proposed to be
required for the biogenesis of MVBs, is also needed for HIV-1 release (reviewed in
[51, 65]. This led to the idea that HIV-1 budding, and consequently Gag-targeting, are
linked to late endosomes/MVBs. Data supporting the role for the endocytic pathway
in HIV-1 budding and/or Gag targeting using various cell types mostly relied on light
microscopy, often using CD63 as a presumed MVB marker [130-132, 144, 145]. By
EM, however, CD63 was found throughout the endocytic pathway including the cell
surface [91] and is not particularly enriched on MVBs, as was shown in the first part
of this study. It is questionable whether double-labeling experiments at the light
microscopy level can discriminate between CD63-positive plasma membrane
domains, MVBs and late endosomes (for a review see [146]) and such data should
thus be interpreted with caution. The fact that the late endosome/lysosome marker
lamp-1 also localized partially to the cell surface of macrophages together with the
finding that Tfr, often used as a marker for early/recycling endosomes, localized
predominantly to late endocytic membranes of these cells, indicated that the use of
marker proteins may not be sufficient for most quantitative microscopic analyses.
Given our unequivocal results in primary macrophages and T cells, we
propose that plasma membrane budding of HIV-1 predominates in most cells. EM
images obtained in HeLa and 293T cell lines apparently showing budding of
retroviruses into endosomes [131, 132], require a re-evaluation using the two markers
(RR-stain and internalized gold) used in the present study.  Thus, our present data,
together with the EM localization of ESCRT in primary T cells and macrophages,
question the proposed pivotal role of MVBs in the HIV-1 life cycle.
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4.3 Future directions
For further study of HIV-1 infection in macrophages it will be important to
analyze in vivo differentiated macrophages by EM. Whether their morphology is
comparable to that of cells cultured in vitro and whether the sites of HIV-1 budding
and release are identical is unknown, since no ultrastructural HIV infection study has
been done yet with ex vivo macrophages. Culture and HIV-1 infection of explanted
human tonsils has been recently established in the lab of Oliver T. Keppler ([147] and
unpublished results), and EM analysis of HIV-1 infected tonsil histoculture can easily
be done in the near future. First experiments indicated that tonsils contain
macrophages that look very similar to the in vitro cultured cells. However,
identification of macrophages was based on morphological similarity, and
macrophage-specific surface markers will be needed to identify these cells in the
tissue. Furthermore, the accessibility of the tissue for the cell surface stain RR is
inefficient, most likely due to tight cell-cell contacts, and it will therefore be
challenging to analyze the organization of cell surfaces inside tissues. Since
macrophages were previously proposed to store infectious HIV-1 in endosomal
compartments for long periods [38] it will be important to formally demonstrate if
infectious virus can be stored in plasma membrane invaginations of macrophages or
other cell types.
The concentration of CD63 on virus particles suggested that HIV-1 budding
occurred from plasma membrane regions where CD63 was enriched. Although we
could show that CD63 accumulated in extended regions of the plasma membrane, it
was not possible to determine if HIV-1 budding predominated in these regions.
Statistic analysis was mainly hampered by the low numbers of budding structures
observed, and therefore a testable system, yielding higher numbers of budding sites,
could result from using HIV-1 L-domain mutants displaying a late budding defect.
From our finding that several vacuolar structures of macrophages were not
stained with RR (although the presence of filopodia and clathrin coated pits clearly
showed that they were limited by the plasma membrane) we concluded that this RR-
inaccessibility was due to technical reasons. Another possibility for formation of such
RR-inaccessible vacuoles would be membrane fusion of adjacent cells. Such cell-cell
fusion events, induced by HIV-1 Env expression on the cell surface, were shown to
occur frequently in HIV-1 infected macrophages and are known to lead to syncytia
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formation. Whether RR negative vacuolar structures of macrophages (or other cell
types) are a result of cell-cell fusion could be tested using viral constructs encoding
fusion-deficient Env glycoprotein.
Since our EM data suggest a role for ESCRT in protein sorting and recycling,
further experiments will be required to determine whether sorting of ubiquitinated
proteins into the lysosomal degradation pathway is the predominant function of
ESCRT in the endocytic pathway. Furthermore, for future studies of ESCRT in HIV-1
infected cells it will be important to address the functional roles of different ESCRT
subunits in HIV-1 budding and release. Whereas abrogation of ESCRT binding to
Gag (by mutation of L domains in Gag, or Tsg101 depletion) was proposed to lead to
induce an ‘early’ HIV-1 budding arrest (represented by crescent-shaped budding
sites), overexpression of dnVps4 is thought to lead to a late HIV-1 budding arrest
(represented by ‘lollipop’ shaped budding sites) due to a block in membrane fission.
However, this model has not been proven yet. This could be addressed by interfering
with ESCRT-Gag interactions and ESCRT function by different means, e.g. by
making use of truncated or mutated Gag constructs lacking the p6 domain or L
domain motifs, respectively, by RNA interference with expression of Tsg101 and
Aip1/Alix or by overexpression of dnVps proteins. Whether this correlates with
distinct HIV-1 budding phenotypes can be addressed by quantitative EM and will
now be studied by Stefanie Jaeger, a PhD student in our lab.
Finally, one could address the question whether ESCRT association with
membranes is mediated solely by Hrs or if ESCRT proteins can participate in other,
yet unknown, interactions with membrane- or membrane-associated proteins. Such
proteins, e.g. bearing PT/SAP motifs, could serve as alternative binding partners for
Tsg101. Another possibility would be that ESCRT subunits, similar to what was
proposed for Aip1/Alix [119], directly interact with membrane lipids.
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Appendix I    List of abbreviations
µl microliter
µm micrometer
aa amino acid
Aip1/Alix Apoptosis-linked gene 2 (ALG-2)-interacting protein 1/
ALG-2-interacting protein X
APS Ammonium persulfate
BIS N,N’-methylene bisacrylamide
bp Base pair
BSA bovine serum albumine
BSA gold collidal gold particles coupled to BSA
CA Capsid protein
cm centimeter
DDSA 2-Dodecenylsuccinic acid anhydride
dH2O deionized water
DMP-30 2,4,6 Tris(dimethylaminomethyl)phenol
dn dominant negative
DNA deoxyribonucleic acid
EGTA ethylene glycol-bis(?-aminomethylether)-N,N,N’,N’-
tetraacetic acid)
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
ESCRT endosomal sorting complex required for transport
EtOH ethanol
GA glutaraldehyde
Gag Group specific antigen
gp glycoprotein
HAB human AB serum
HEPES N-2-hydroxyethylpiperazine-N’-2-ethane sulfonic acid
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HIV human immuno deficiency virus
hrs hours
Hrs hepatocyte growth factor kinase substrate
IF immunofluorescence
kb kilobase
kDa kilodalton
KOH potassium hydroxide
M molar; mol/liter
MA Matrix protein
MC methyl cellulose
min minute(s)
ml milliliter
mm millimeter
MNA methylnadic anhydride
NaCl sodium chloride
NC nucleocapsid protein
nm nanometer
ºC degrees centigrade
p pico
p.i. post infection
PAG protein A gold
PBG immuno-EM blocking solution (PBS/BSA/gelatin)
PBS phosphate buffered saline
PBST PBS with 0.1% Tween-20
PFA paraformaldehyde
PIPES piperazine-N,N’-bis(2-ethane sulfonic acid)
PR Protease enzyme
PVDF polyvinylidene fluoride
RNA ribonucleic acid
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RR Ruthenium Red
RT reverse transcriptase enzyme
SDS sodium dodecyl sulfate
SDS-PAGE SDS-polyacrylamide gel electrophoresis
TEM transmission electron microscope
TEMED N,N,N’N’-tetramethylenediamine
Tsg101 Tumor susceptibility gene 101 protein
U unit
UA uranyl acetate
Vps vacuolar protein sorting
wt wild type
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Appendix III   Preparation of BSA gold
stock solutions required:
• 1% (w/v) gold chloride in dH2O (Sigma #G-4022). Can be stored for several
weeks at 4ºC, protect from light.
• 1% (w/v) tri-sodium citrate· 2H2O in dH2O
• 1% (w/v) tannic acid in dH2O (Serva #35753), prepare freshly
• 25mM potassium carbonate in dH2O
• 20% (w/v) BSA in dH2O (Biomol #01400, BSA Fraction V)
gold
conden-
sation
5nm gold 10nm gold 16nm gold
gold
solution
A
790ml dH2O
10ml 1% AuCl2
790ml dH2O
10ml 1% AuCl2
960ml dH2O
10ml 1% AuCl2
reducing
solution
B
40ml  1% tri-Na
citrate
10ml 1% tannic acid
10ml 25mM K2CO3
140ml dH2O
20ml 1% tri-Na
citrate
40ml  1% tri-Na citrate
0.5ml 1% tannic acid
159.5ml dH2O
Heat each solution to 60ºC
Quickly pour B into A while rapidly stirring,
color of solution changes to red immediately,
heat up to 95ºC for 5 min
Heat  solution A to 100ºC
while stirring
quickly add 20 ml 1% tri-Na
citrate
re-heat to 100ºC until color
changes to red
BSA coupling
let cool down to room temperature
adjust pH using pH paper to the isoelectric point of BSA (~pH 7.0). Colloidal
gold blocks pH electrode!
Add 10ml 20% BSA (final BSA concentration 0.2%), stir slowly for 10 min
Centrifugation (all steps at 4ºC)
Beckman
45 Ti
45.000 rpm, 90 min
remove supernatant, resuspend pellet
carefully in 0.2%BSA/PBS
8.000 rpm, 45 min,
remove supernatant,
resuspend pellet carefully in
0.2%BSA/PBS
Beckman
70 Ti
38.000 rpm, 30 min
collect supernatant
18.000 rpm 30 min
collect supernatant
Beckman
70 Ti
spin supernatant at
45.000 rpm,
30 min
spin supernatant at
27.000 rpm,
30 min
remove supernatant
resuspend pellet carefully in 0.2%BSA/PBS
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Appendix IV  Immunolabeling
- place grids section-side-down on 2 %
gelatin plate, incubate to melt away
gelatin
> 20 min at 37°C
at room temperature, grids section-side-down on a drop of solution
- wash 4x 2 min, PBS
- block 10 min, PBG
- primary antibody 30 min, diluted in PBG
- wash 5x 2 min, PBS
if required:
- rabbit-anti-mouse bridging
antibody
30 min, diluted in PBG
- wash 5x 2 min, PBS
- protein A gold (PAG) 20 min, diluted in PBG
- wash 5x 2 min, PBS
- wash 5x 2 min, ddH2O
for double labeling experiments:
- fix 5min, 2% GA in ddH2O
- wash 5x 2 min, PBS-glycine
- wash 3x 2 min PBS
- block 10 min, PBG
- antibody-, PAG-incubation and wash steps as above
on ice:
- contrast
3-10 min, 2%MC /3%UA  (mixed 0.85+
0.15)
- loop out grids from MC/UA solution
at room temperature:
- dry on Whatman #1 filter paper
- air-dry ~10 min
- store in grid box at room temperature forever
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